

Organization IC1600 Bldg./Room REHUSEN
U. S. DEPARTMENT OF COMMERCE
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450
IF UNDELIVERABLE RETURN IN TEN DAYS
OFFICIAL BUSINESS

AN EQUAL OPPORTUNITY

RECEIVED

JAN 21 2005

TECH CENTER 1600/2900



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/009,643	12/12/2001	Michael O. Thorne	033493-001	9752
21839	7590	01/18/2005	EXAMINER	
BURNS DOANE SWECKER & MATHIS L L P			KAUFMAN, CLAIRE M	
POST OFFICE BOX 1404			ART UNIT	
ALEXANDRIA, VA 22313-1404			PAPER NUMBER	

1646

DATE MAILED: 01/18/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/009,643	Applicant(s) THORNER ET AL.	
	Examiner Claire M Kaufman	Art Unit 1646	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 12 January 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-7 and 9-17 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-7 and 9-17 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, 2, 3, 4 and 14, drawn to a ligand that binds and/or activates the GHRH receptor of SEQ ID NO:4, and a nucleic acid of SEQ ID NO:6 encoding a ligand.

Group II, claim(s) 5-7 and 15, drawn to a chicken GHRH receptor and encoding nucleic acid.

Group III, claim(s) 9-12, drawn to method of enhancing feed utilization or growth in an avian by administration of an agonist or antagonist, including a ligand, of the GHRH receptor of SEQ ID NO:4.

Group IV, claim(s) 13, drawn to method of enhancing feed utilization in an avian by administering a compound that up-regulates the expression of the GHRH receptor of SEQ ID NO:4.

Group V, claim(s) 16, drawn to a transgenic avian comprising a nucleic acid encoding a ligand of the GHRH receptor of SEQ ID NO:4.

Group VI, claim(s) 17, drawn to a transgenic avian comprising a nucleic acid encoding a chicken GHRH receptor.

The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

According to PCT Rule 13.2, unity of invention exists only when the shared same or corresponding technical feature is a contribution over the prior art. The inventions listed as Groups I and III do not relate to a single general inventive concept because of the lack of the same or corresponding special technical feature. The technical feature of Group I is a ligand that binds the chicken GHRH receptor of SEQ ID NO:4, which is shown by WO 98/32857 to lack

Art Unit: 1646

novelty or inventive step because of the teaching of a human GHRH (a.k.a. GRF, page 11, lines 25-29) which, according to the instant specification (page 14, lines 15-27), binds to the chicken GHRH (cGHRH) receptor of SEQ ID NO:4, and does not make it a contribution over the prior art.

According to PCT Rule 13.2, unity of invention exists only when there is a shared same or corresponding technical feature among the claimed inventions. All the groups are directed to a GHRH ligand, receptor or method of using the ligand or receptor or nucleic acid thereof, but each group has a different special technical feature not shared by the remaining groups. Group I is directed to a GHRH ligand, which has the special technical feature of being a ligand that binds and/or activates the GHRH receptor of SEQ ID NO:4, which is not shared by any of the remaining groups (see preceding paragraph for why special technical feature is not shared with methods using the ligand Group III). Group II is directed to a GHRH receptor which has the special technical feature of its structure and function, which is not shared by any of the remaining groups. Group IV is directed to a method of administering a compound which up-regulates expression of a GHRH receptor and is not the first methods and which has the special technical feature of different method steps and outcomes, which is not shared by any of the remaining groups. Group V is directed to a transgenic avian comprising a nucleic acid encoding a ligand of Group I, however, it has the special technical feature of being an avian comprising the particular nucleic acid, which is not shared by any of the remaining groups. Group VI is directed to a transgenic avian comprising a nucleic acid encoding a receptor of Group II, however, it has the special technical feature of being an avian comprising the particular nucleic acid, which is not shared by any of the remaining groups.

This Authority therefore considers that the several inventions do not share a special technical feature within the meaning of PCT Rule 13.2 and thus do not relate to a single general inventive concept within the meaning of PCT Rule 13.1.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

Art Unit: 1646

application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.**

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Claire M. Kaufman, whose telephone number is (571) 272-0873. Dr. Kaufman can generally be reached Monday, Tuesday and Thursday from 8:30AM to 2:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached at (571) 272-0829.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Art Unit: 1646

Official papers filed by fax should be directed to (571) 273-8300. NOTE: If applicant *does* submit a paper by fax, the original signed copy should be retained by the applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office. **Please** advise the examiner at the telephone number above before facsimile transmission.

Claire M. Kaufman, Ph.D.

A handwritten signature in cursive script, appearing to read "Claire M. Kaufman".

Patent Examiner, Art Unit 1646

January 13, 2005

Notice of References Cited	Application/Control No. 10/009,643	Applicant(s)/Patent Under Reexamination THORNER ET AL.	
	Examiner Claire M Kaufman	Art Unit 1646	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	WO 9832857 A1	07-1998	World Intellect	SHERWOOD et al.	-----
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

[illegible]

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CHICKEN NEUROPEPTIDE GENE USEFUL FOR POULTRY PRODUCTION

Field of the invention

5 This invention relates to the improvement of poultry production through the use of recombinant neuropeptides. The invention is premised on the discovery of gene sequences from chicken encoding the neuropeptides GRF (Growth Hormone Releasing Hormone) and PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide).

10 Background of the invention

Poultry is a major source of protein in the western diet. However, the result of many years of breeding selection for fast-growing chickens and turkeys has resulted in the production of commercial poultry strains which have increased fat deposits. Because of this increased fat content, some nutritionists no longer recommend poultry over trimmed red meat. In addition, four times as
15 much feed is required to produce 1 gram of fat compared to 1 gram of muscle, and so this increased fat content also elevates production costs (notably, the cost of feed represents over half of the expense of raising poultry—69 % for broiler chickens, 61 % for turkeys). Accordingly, the ability to produce poultry with a lower fat content would have both health and economic benefits.

Growth Hormone-Releasing Hormone (GHRH or GRF) and Pituitary Adenylate Cyclase-
20 Activating Polypeptide (PACAP) are two members of the glucagon superfamily of proteins. They are neuropeptides which, amongst other activities, stimulate the release of pituitary growth hormone (GH), the major growth hormone in animals. In human studies, recombinant GH has been shown to increase lean body mass and reduce fat content in elderly adults. By extrapolation, the regulation of GH in agricultural animals may be useful to control growth rates and body composition.
25 Accordingly, there is much interest in GRF and PACAP, and a major focus of the ongoing research is the search for genes which encode these neuropeptides in agriculturally important animal species, including poultry.

Although rat and human GRF have been shown to stimulate GH release from chicken
pituitary cells in vitro, a chicken GRF has not yet been reported. It is a goal of the present invention
30 to provide neuropeptide gene sequences and peptide sequences which function to stimulate GH release in poultry.

Summary of the invention

This invention provides, for the first time, a gene from chicken which encodes a precursor polypeptide for both GRF and PACAP (this gene is referred herein to as the chicken GRF/PACAP
35 gene). The chicken GRF/PACAP gene sequence is provided, along with 5' and 3' regulatory sequences which regulate expression of the gene. Also provided are the amino acid sequences of the peptides encoded by this gene (because of alternative splicing of the introns in the gene, three different mRNAs, encoding three slightly different peptides, are produced). This invention permits

the generation of nucleotide sequences encoding either the GRF/PACAP precursor polypeptide or the individual GRF or PACAP peptides, or both of these individual peptides.

Other aspects of the invention involve recombinant cloning vectors including nucleotide sequences encoding the chicken GRF and/or PACAP peptides, and transgenic host cells transformed with such cloning vectors. Genetic constructs designed for optimal expression of the chicken PACAP and/or GRF peptides are also provided. These constructs include nucleotides encoding the chicken GRF/PACAP precursor peptide or the individual chicken PACAP or GRF peptides in association with regulatory sequences which control the expression of the coding sequences. For example, a cDNA molecule encoding the chicken GRF may be functionally linked to the 5' promoter region found upstream of the chicken GRF/PACAP gene.

Also encompassed by this invention are nucleotide sequences which include less than the entire chicken GRF/PACAP gene. For example, oligonucleotide primer and probe sequences which are derived from the nucleotide sequences provided are included within the scope of the invention. Such sequences, which are typically 10-50 nucleotides in length are useful, amongst other things, for amplifying the chicken gene from various tissues, performing hybridization studies and for cloning corresponding gene sequences from other species. Nucleotide sequences which encode larger sub-parts of the chicken GRF/PACAP are also part of the invention. Such sequences include, for example, DNA molecules encoding the individual GRF and PACAP peptides, as well as regulatory regions useful in controlling gene expression. These sequences preferably include at least 10 contiguous nucleotides of the disclosed GRF/PACAP gene sequence (and more preferably at least 25, 30 or at least 50 contiguous nucleotides). In other embodiments, these nucleotide sequences encode a peptide capable of stimulating the release of pituitary growth hormone from chicken pituitary cells.

The provision of the chicken GRF/PACAP gene sequence also enables the cloning of related genes from other species, and the production of variants on the disclosed gene sequence. These variant sequences are defined as sequences which hybridize under conditions of at least 75% stringency to the disclosed sequences and which retain the characteristic of encoding a polypeptide capable of stimulating the release of pituitary growth hormone from chicken pituitary cells.

Another aspect of the invention are the purified chicken GRF and PACAP peptides. The peptides may be purified from cell extracts, for example from host cells transformed with a recombinant vector expressing the peptides, or they may be synthesized by standard peptide synthesis methods. Purified GRF and PACAP peptides may be administered to animals directly to modulate GH levels and thereby regulate body composition and growth rates. For example, the purified peptides may be administered orally to chicks in feed, or may be formulated into slow release pellets which are administered subcutaneously. Such slow-release pellets comprise the peptide combined with a biocompatible matrix, such as cholesterol. Other methods of administration include injection of the peptides incorporated into a biocompatible matrix, and the use of mini osmotic pumps. The amino acid sequences of the disclosed GRF, PACAP and GRF/PACAP precursor polypeptides may

also be modified in exact sequence, while retaining the characteristic function of stimulating the release of pituitary growth hormone from chicken pituitary cells. Such variant amino acid sequences preferably include a stretch of at least 20 consecutive amino acids identical to the amino acid sequence of the disclosed peptides.

- 5 The nucleotide sequences disclosed herein may also be used to enhance the growth rate or improve the body composition of farmed animals. For example, genetic constructs including the chicken GRF/PACAP gene may be introduced into chicken primordial germ cells to produce genetically altered chickens. Successful integration of such constructs into the chicken genome will produce a bird carrying additional copies of the GRF/PACAP gene which, in turn, would be
- 10 expected to produce higher levels of the GRF/PACAP polypeptide and thereby elevated levels of pituitary GH. Even higher levels of GRF/PACAP expression may be obtained by using GRF/PACAP constructs in which the open reading frame is operably linked to a promoter known to direct high level expression of downstream gene sequences. Promoter sequences specific for particular tissues (e.g. brain or gonads) or particular developmental stages may also be employed.
- 15 The present invention also facilitates the ready detection of transgenic birds carrying introduced GRF/PACAP constructs.

Brief description of the drawings

- Fig. 1 shows the subclone organization of the chicken GRF/PACAP gene and the cDNA encoding the GRF/PACAP precursor polypeptide, together with the location of PCR primers.
- 20 Fig. 2 shows the nucleotide sequence of the chicken GRF/PACAP gene. Nucleotides comprising subclones 1.8, 3.1, and 3.2 are shown along with the intron/exon boundaries and the 5'- and 3'- flanking regions. The translated amino acid sequence is shown in the single letter code below the nucleotide sequence of coded exons and both sequences are numbered on the right. The nucleotide
- 25 numbering begins at the beginning of the clone, whereas the amino acid numbering begins at the initiating methionine. GRF is underlined with a solid line and PACAP is underlined with a dotted line. All exons are in bold capital letters with the first exon being composed completely of 5'UTR. GRF₁₋₄₆ is encoded on two exons. The intervening intron has alternate splice sites. The intron-exon boundary for nucleotides encoding the second part of GRF₁₋₄₆ is shown (+). The other splice site,
- 30 9bp toward the 3' end, is shown by the double symbol (+ +). This splice site removes nine nucleotides resulting in a shortened GRF₁₋₄₃. Only a portion of the nucleotides that encode the promoter region and intron 2 and 4 are shown. The remaining nucleotides are provided in Seq. I.D. No. 1. Within the promoter, the CAAT and TATAAA sequence motif have been underlined.

35 Sequence listing

The accompanying sequence listing comprises the following sequence information:

Seq. I.D. No. 1: complete nucleotide sequence of the chicken GRF/PACAP gene.

Seq. I.D. No. 2: full length cDNA encoding chicken GRF/PACAP neuropeptide precursor.

Seq. I.D. No. 3: amino acid sequence of the peptide encoded by full length cDNA shown in Seq. I.D. No. 2 (including 46 amino acid GRF peptide and 38 amino acid PACAP peptide).

Seq. I.D. No. 4: amino acid sequence of the 46 amino acid GRF peptide encoded by full length cDNA shown in Seq. I.D. No.2.

5 Seq. I.D. No. 5: amino acid sequence of the 38 amino acid PACAP peptide.

Seq. I.D. No. 6: alternatively spliced cDNA sequence encoding chicken GRF/PACAP neuropeptide precursor (alternatively spliced cDNA #1).

Seq. I.D. No. 7: amino acid sequence of the peptide encoded by alternatively spliced cDNA #1 (including 43 amino acid GRF peptide and 38 amino acid PACAP peptide).

10 Seq. I.D. No. 8: amino acid sequence of the 43 amino acid GRF peptide encoded by alternatively spliced cDNA #1.

Seq. I.D. No. 9: alternatively spliced cDNA sequence encoding chicken GRF/PACAP neuropeptide precursor (alternatively spliced cDNA #2).

15 Seq. I.D. No. 10: amino acid sequence of the peptide encoded by alternatively spliced cDNA #2 (including 14 amino acid truncated GRF peptide and 38 amino acid PACAP peptide).

Seq. I.D. No. 11: nucleotide sequence encoding chicken 43 amino acid GRF peptide.

Seq. I.D. No. 12: nucleotide sequence encoding chicken 46 amino acid GRF peptide.

Seq. I.D. No. 13: nucleotide sequence encoding chicken 38 amino acid PACAP peptide.

Seq. I.D. No. 14: nucleotide sequence of primer D used in PCR amplification.

20 Seq. I.D. No. 15: nucleotide sequence of primer F used in PCR amplification.

Seq. I.D. No. 16: nucleotide sequence of primer A used in PCR amplification.

Seq. I.D. No. 17: nucleotide sequence of primer 1 used in PCR amplification.

Seq. I.D. No. 18: nucleotide sequence of primer 2 used in PCR amplification.

25 Seq. I.D. No. 19: amino acid sequence of PACAP 27 (PACAP 27 is a form of PACAP which results from alternative post-translational processing).

Seq. I.D. No. 20: amino acid sequence of GRF 29 (the first 29 amino acids of GR, this is believed to represent the minimally active unit of GRF).

Detailed description of the invention

30 I. Definitions

Particular terms and phrases used have the meanings set forth below.

Isolated: An "isolated" nucleic acid has been substantially separated or purified away from other nucleic acid sequences in the cell of the organism in which the nucleic acid naturally occurs, i.e., other chromosomal and extrachromosomal DNA and RNA. The term "isolated" thus
35 encompasses nucleic acids purified by standard nucleic acid purification methods. The term also embraces nucleic acids prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids.

cDNA (complementary DNA): a piece of DNA lacking internal, non-coding segments (introns) and regulatory sequences which determine transcription. cDNA is synthesized in the laboratory by reverse transcription from messenger RNA extracted from cells.

5 ORF (open reading frame): a series of nucleotide triplets (codons) coding for amino acids without any termination codons. These sequences are usually translatable into a peptide.

Probes and primers: Nucleic acid probes and primers may readily be prepared based on the nucleic acids provided by this invention. A probe comprises an isolated nucleic acid attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. Methods for labeling and guidance in the choice of labels
10 appropriate for various purposes are discussed, e.g., in Sambrook et al. (1989) and Ausubel et al. (1987).

Primers are short nucleic acids, preferably DNA oligonucleotides 15 nucleotides or more in length. Primers may be annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and the target DNA strand, and then extended
15 along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR) or other nucleic-acid amplification methods known in the art.

Methods for preparing and using probes and primers are described, for example, in Sambrook et al. (1989), Ausubel et al. (1987), and Innis et al., (1990). PCR primer pairs can be derived from a
20 known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, © 1991, Whitehead Institute for Biomedical Research, Cambridge, MA).

Purified: the term purified does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified peptide or protein preparation is one in which the protein referred to is more pure than the protein in its natural environment within a cell.

25 Operably linked: A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein coding regions, in the same
30 reading frame.

Recombinant: A recombinant nucleic acid is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic
35 engineering techniques.

GRF: Growth hormone-releasing hormone (alternatively referred to as GHRH).

PACAP: Pituitary adenylate cyclase-activating polypeptide.

GRF/PACAP precursor polypeptide: a polypeptide which includes both GRF and PACAP polypeptide sequences. Cleavage of this precursor polypeptide yields the individual GRF and PACAP polypeptides and a cryptic polypeptide.

Additional definitions of common terms in molecular biology may be found in Lewin, B.

5 "Genes IV" published by Oxford University Press.

II. Cloning of chicken GRF/PACAP gene

A. Materials and methods

1. DNA amplification

10 i. Amplification of the chicken GRF/PACAP mRNA 3' end

Chicken (*Gallus domesticus*) brains were removed, placed immediately in liquid nitrogen and stored at -80°C. Total RNA was extracted with an acidic guanidinium thiocyanate method (Chomczynski and Sacchi, 1987), followed by purification of poly A⁺ rich mRNA on two
15 consecutive oligo dT₁₂₋₁₈ columns. Single stranded cDNA was synthesized with 10µg poly A⁺ rich mRNA, 2mM oligo dT₂₀ (primer E), 5 times Superscript buffer, 2mM dNTP, 10mM DTT, 5U RNA guard (Pharmacia), and 200 U RT Superscript (BRL) to a final volume of 25µl. The reaction was heated to 42°C for 1.25hr and terminated by increasing the temperature to 95°C for 10 min.

Amplification was performed in a 50µl volume with 0.2µg cDNA, 5U Taq, 1x Taq buffer
20 (Promega), 200mM dNTP's, 2.5mM MgCl₂ and 20 pmol of primers D (5'-
caigtgttgacagacacacacgtgagcg) (Seq. I.D. No. 14) and F (5'-cattcggatgggatcttcacggatag) (Seq. I.D. No. 15). The reaction was carried out for 35 cycles at 94°C for 1 min, 45°C for 1.5 min, 72°C for 1.5 min and for a 5.3 min extension at 72°C. Amplified bands were cloned into pBluescript KS+ (Stratagene), electroporated into XL-1 competent cells, and prepared for sequencing with an alkaline
25 hydrolysis method (Birnbom 1983). Both strands were sequenced with [α -³⁵S] dATP using the USB Sequenase chain termination method (Sanger *et al.*, 1977) and CircumVent thermal cycle sequencing kit (New England Biolabs). All sequencing gels were 6% polyacrylamide/7M urea wedge gels, dried under vacuum at 80°C and exposed to Kodak XAR-5 film for 12-24h.

30 ii. Amplification of the 5' end

A modified version of Frohman's (1988) RACE protocol was utilized to amplify the 5' end of the chicken GRF/PACAP cDNA. To amplify the 5' end, 1µg Poly A⁺ mRNA was mixed with 10pmol primer D, and 7µl DEPC treated water to a final volume of 10µl, heated at 65°C for 5min, and then cooled on ice. Single stranded cDNA was synthesized with the above mRNA/primer
35 mixture, 5µl Superscript buffer, 1µM dNTP, 10mM DTT, 5U RNA guard (Pharmacia), and 200 U RT Superscript (BRL) to a final volume of 25µl. The reaction was heated to 42°C for 1.25hr and terminated by increasing the temperature to 95°C for 6min. The first strand synthesis was concentrated to 12.5 µl, of which 10µl was extended with dATP, 1µl water and 1µl TdT enzyme

(BRL). PCR conditions were identical to the above except for the use of primers D and E (oligo dT₂₀).

iii. Amplification of GRF/PACAP mRNA splice variants

5 Brains were removed from 25-day-old chickens and extracted in TriZol (BRL). Complementary DNA was synthesized from 1 μ g of total RNA using 200U avian reverse transcriptase (H⁻ RT Superscript, BRL), 10mM DTT, 0.5mM each dNTP, 50U RNA guard, 2 μ M primer E, and 1X H⁻ RT buffer for a total reaction volume of 20 μ l. The reaction proceeded for 90min at 41°C followed by 10 min at 90°C. PCR amplifications were done with 0.5 μ l of newly
10 transcribed single stranded cDNA from each tissue, 5U Taq DNA polymerase, 1x Taq buffer (Promega), 0.2mM each dNTP, 0.4 μ M of primers A (5'-gagccccgccggtgcttaccgcag) (Seq. I.D. No. 16) and D (Fig. 1), and 2.5mM MgCl₂ in a 50 μ l reaction for 35 cycles (94°(1')-55°(1.5')-72°(1.75')). PCR reactions were purified through a 1.5% agarose gel. Bands were isolated, cloned into pBluescript KS+ (Stratagene), electroporated into XL-1 competent cells, and prepared for
15 sequencing with an alkaline hydrolysis method (Birnboim 1983). Both strands were sequenced with [α -³⁵S] dATP using the USB Sequenase chain termination method (Sanger *et al.*, 1977) and CircumVent thermal cycle sequencing kit (New England Biolabs).

iv. Reverse transcriptase/PCR assay

20 Brain, ovary/oviduct, testis, pituitary, heart, liver, kidney, crop, small intestine, large intestine, eye, and the muscle were removed from 25-day-old chickens and extracted in TriZol (BRL). Complementary DNA was synthesized from 1 μ g of total RNA using 200U avian reverse transcriptase (H⁻ RT Superscript, BRL), 10mM DTT, 0.5mM each dNTP, 50U RNA guard, 2 μ M primer E, and 1X H⁻ RT buffer for a total reaction volume of 20 μ l. The reaction proceeded for
25 90min at 41°C followed by 10 min at 90°C. PCR amplifications were done with 0.5 μ l of newly transcribed single stranded cDNA from each tissue, 5U Taq DNA polymerase, 1x Taq buffer (Promega), 0.2mM each dNTP, 0.4 μ M of primers A and D (Fig. 1), and 2.5mM MgCl₂ in a 50 μ l reaction for 35 cycles (94°(1')-55°(1.5')-72°(1.75')).

30 2. Genomic library screening

A total of 10⁶ pfu from the chicken genomic library (Stratagene) were screened with the 294bp PCR cDNA fragment (primers D/F). Duplicate nylon membrane (BioRad) lifts were prehybridized at 50°C in 6x SSC, 5x Denhardt's solution, 0.5% SDS and 30mg/ml sea urchin DNA (blocking DNA) for 4 hours. The hybridization solution, consisting of 6x SSC, 0.5% SDS, and
35 100mg blocking DNA, was added to the [α -³²P]dCTP (Dupont) labeled probe (2.4x10⁷ cpm/ml) and incubated at 50°C overnight. The membranes were washed under high stringency (0.1xSSC/0.1%SDS) for 50 min at 50°C, then exposed to Kodak XAR-5 film for 7 days at -80°C.

Three additional rounds of screening were used to purify a positive clone that had been isolated from the genomic library. The insert was excised from the phage DNA with SacI, purified by agarose gel electrophoresis and subcloned into pBluescript KS (Stratagene) using T4 Ligase (Pharmacia). Three of the four SacI subclones were shortened by nested deletions (double stranded nested deletion kit, Pharmacia) on both strands followed by sequencing of the two strands, according to the manufacturer's instruction.

3. Southern analysis

Chicken liver DNA was ground and treated with proteinase K (Sigma) in buffer (10mM Tris, pH 8; 100mM EDTA, pH 8; 0.5% SDS; 200µg/ml proteinase K) overnight at 55°C. The DNA was purified with three subsequent phenol:chloroform:isoamyl alcohol extractions (24:24:1) and one chloroform:isoamyl (24:1) extraction; end-over end mixing was carried out for 3 hours after each addition of fresh phenol-chloroform-isoamyl alcohol. The DNA was dialyzed against TE (pH 8) overnight to remove the organic solvents. 10µg (30µl) DNA was digested with either EcoRI, SacI, HindIII, PvuII, and KpnI and electrophoresed through a 1% agarose gel, in duplicate. The DNA was transferred as to the manufacturer's specification (BioRad) for the alkaline Zeta-Probe GT membrane. Prehybridization was in 7% SDS, 0.25M NaHPO₄, pH 7.2, 1mM EDTA at 65°C for 15min. Hybridization was in fresh prehybridization solution plus the random primed α-³²P[dCTP] labeled probe for 17hr at 65°C. The hybridized membranes were rinsed under low stringency (45°C) with 5%SDS, 40mM NaHPO₄, 1mM EDTA and then washed for 45min with fresh solution (45°C). The wash solution was raised to high stringency (65°C) by washing with 1% SDS, 40mM NaHPO₄, 1mM EDTA and washed twice for 45min at 65°C with fresh solution. After washing, the membranes were sealed in plastic and exposed 24hr to Kodak Biomax film with intensifying screens at -80°C.

B. Results

1. Gene organization

A single band of 294bp resulted from the first DNA amplification of chicken RNA/cDNA. This cDNA fragment was used to screen the chicken genomic library. One million clones were screened to produce a single plaque that hybridized to the probe. The lambda clone of approximately 12500bp, produced 4 fragments when digested with SacI (Figure 1). These smaller fragments were purified and subcloned into pBluescript KS (subclones 1.8, 3.1, 3.2, and 4.4).

Subclones 1.8, 3.1 and 3.2 contained 6469bp of the chicken GRF/PACAP gene; clone 4.4 consisted of approximately 5Kb of 3' flanking region and therefore was omitted. Subclone 1.8 (1682bp) contained exons 3, 4, and 5 encoding the cryptic peptide, GRF, and PACAP, respectively. Exon 3 containing part of the cryptic peptide was 134bp in length and contained the nucleotide reading frame that encodes a dibasic processing site (Lys-Arg) between the cryptic and GRF peptide. Exon 4 has 96 nucleotides that code for the initial 32 amino acids of chicken GRF. The final

portion of GRF on exon 5 shows that chicken GRF is unique because it is 46 amino acids, the longest known GRF. On exon 5 immediately downstream of the coding region of chicken GRF₁₋₄₆ is the coding region for PACAP₁₋₃₈ separated from GRF by a Lys-Arg processing site. The chicken PACAP₁₋₃₈ is identical to the mammalian form except at position #2 which has an isoleucine substituted for an alanine. Clone 3.1 (2160bp) contained exon 1 that encoded the 5'-untranslated region (UTR) (194bp), an intron (142bp) and exon 2 that encoded the signal peptide and a portion of the cryptic peptide (114bp). Clone 3.1 also contained 344bp of regulatory region. Within the 344bp was a CAAT regulatory region at position 2974bp, and the TATAA at position 3002bp; these nucleotides are consensus regulatory regions not found in other *pacap* genes. Intron 2 of 1337bp was the longest intron and introns 3 of 178bp and 4 of 371bp contained an unusually high G/C content and numerous (G)_n repeats. Clone 3.2 (2627bp) was exclusively promoter.

2. Alternative Splicing

To confirm intron-exon boundaries, brain mRNA/cDNA was screened using the PCR and primers A and D. All intron-exon boundaries were confirmed, however the boundary between exons 4 and 5 was found to vary: in some bands, the first boundary was at position 5703bp, the second boundary had slid nine bases downstream to position 5712 bp and the third boundary shows that exon 4 is lacking altogether.

3. Tissue expression

In juveniles at 25 days after hatching, chicken GRF/PACAP mRNA was detected not only in the brain, but also in tissues external to the brain using a RT/PCR method. GRF/PACAP mRNA expression was detected within the brain, ovary/oviduct and testis of the chicken. Expression was not detected within the pituitary, heart, liver, kidney, crop, small intestine, large intestine, eye, or the muscle. From the brain mRNA, two bands were amplified from the RT/PCR method. These two bands, along with the single bands from the ovary/oviduct and testis, were purified and sequenced to verify the PACAP sequence. The longest band in the brain and single band in gonads contained all exons, whereas the shorter band in the brain lacked exon 4. The cDNA appeared to be of good quality as determined by the PCR products obtained with tubulin primers.

4. Southern analysis

Southern analysis of chicken genomic DNA using the 294bp PCR cDNA fragment as a DNA probe revealed two bands. All five genomic DNA restriction digests had two areas hybridizing to the cDNA probe. Both bands appeared when low and high stringency washes were applied to the membrane and no other bands appeared with low stringency washes.

C. Discussion of results

1. Gene organization reveals two neuropeptides encoded in one gene

5 We have isolated from a chicken (c) genomic library a clone that encodes both a GRF peptide and PACAP. This is the first report of an avian GRF. Both PACAP and GRF belong to the glucagon superfamily in which the members have similar intron/exon organization and sequence identity. For example, the amino acid identity between chicken GRF and PACAP is 30%. This organization in which both peptides are encoded on the same gene is similar to that in fish (see U.S. patent application serial No. 08/062,472), but unlike mammals, which have two genes encoding each peptide separately.

15 The association of chicken PACAP (cPACAP) with members of a superfamily including glucagon, secretin, GRF, and vasoactive intestinal peptide (VIP) is illustrated by a high sequence identity between cPACAP and cVIP (Talbot et al., 1995). In comparing mRNAs, the nucleotides encoding the cPACAP region have 80% identity with the nucleotides encoding the cVIP region. This high degree of identity likely explains the observation of two bands hybridizing with the cPACAP probe on Southern blots.

20 The nucleotides of the cPACAP coding region are 92% identical to the human PACAP gene. The deduced cPACAP amino acid sequence is 97% identical to the human sequence with the only change being at position 2 where an isoleucine is substituted for an alanine. In contrast, the chicken GRF (cGRF) peptide has only 42% amino acid identity to human, 47% to rat and 76% to carp GRF (Vaughan et al., 1992). This divergence among species is not surprising in view of the relatively low sequence identity of 68% between human and rat GRF.

25 2. Alternative splicing produces 3 different mRNAs

The chicken GRF/PACAP gene is composed of 5 exons. All 5 exon locations and intron/exon boundaries were confirmed by isolating cDNA clones from the 5' and 3' RACE reactions with adult brain cDNA (Figure 5). However, in sequences of the PCR fragments, we observed that the intron/exon boundary between exons 4 and 5 has considerable variation (Figure 5). The dominate boundary occurs at position 5703bp; the second boundary slides 9bp downstream to position 5712; and the third boundary shows that exon 4 is lacking altogether. At both splice sites nine bases apart, proper consensus splice sites exist. Therefore, the chicken GRF/PACAP mRNA transcript has splice donor sites that encode a 43-amino-acid GRF. The acceptor site was also shown to shift 9bp upstream to encode a GRF of 46 residues. The intron nucleotides at the 5' splice site of intron 4, AG:GT(A) and the last 4 nucleotides of intron 4 at both 3' splice sites (NCAG:C), closely match the splice site consensus sequences as found in vertebrates (Padgett et al., 1986; Green 1991).

35 This pattern of alternative splicing has not been reported for transcripts in this family of peptides. The function of the alternative splicing is not known other than to encode two GRFs of different length with, potentially, two different functions. Recent evidence suggests that human

40

GRF₁₋₄₄ in the chicken may affect somatotroph differentiation in the embryonic chicken pituitary (Porter et al., 1995) and the development of chick neuroblasts and their neurotransmitters (Kentori and Vernadakis 1990). These effects on early brain development and GH-releasing somatotrophs in the pituitary may reflect an early role of GRF₁₋₄₃ and/or GRF₁₋₄₆ in avian systems.

5 The final mRNA transcript synthesized is a cDNA for chicken GRF/PACAP that lacks exon 4, which encodes GRF₁₋₃₂. The critical part of the peptide is thought to be contained in the missing sequence as mammalian GRF₁₋₂₉ is the core required for full biological activity (Ling et al., 1984). The importance of GRF during development is implied by the absence of exon deletion in the embryo prior to hatching. This deletion of exon four has been reported for cDNAs from three other family
10 members (Parker et al., 1993; Seungkwon *et al.*, 1995; Talbot et al., 1995).

As a result of this alternative splicing, three cDNA sequences may be derived from the GRF/PACAP gene. They are as follows:

1. "Full length" cDNA (Seq. I.D. No. 2) encoding
GRF/PACAP precursor polypeptide (Seq. I.D. No. 3) including 46 amino acid GRF peptide (Seq.
15 I.D. No. 4) and 38 amino acid PACAP peptide (Seq. I.D. No. 5).
2. "Alternatively spliced cDNA #1" (Seq. I.D. No. 6) encoding GRF/PACAP precursor
polypeptide (Seq. I.D. No. 7) including 43 amino acid GRF peptide (Seq. I.D. No. 8) and 38 amino
acid PACAP peptide (Seq. I.D. No. 5).
3. "Alternatively spliced cDNA #2" (Seq. I.D. No. 9) encoding GRF/PACAP precursor
20 polypeptide (Seq. I.D. No. 10) including the presumptively non-functional 14 amino acid truncated
GRF peptide and 38 amino acid PACAP peptide (Seq. I.D. No. 5).

The nucleotide sequences comprising the open reading frames of the 43 and 46 amino acid GRFs and the 38 amino acid PACAP are shown in Seq. I.D. Nos. 11, 12 and 13, respectively.

25 III. Physiological activity of GRF/PACAP neuropeptides

In animal systems studied to date, purified GRF and PACAP have been shown to stimulate the release of GH. For example, PACAP releases GH from mouse and rat clonal pituitary cell lines (Propato-Mussafiri et al., 1992), and human GRF initiates the release of GH from chicken pituitary cells both in vitro (Perez et al., 1987) and in vivo (Scanes and Harvey, 1984). The ability of
30 purified GRF and PACAP to stimulate GH release may therefore be regarded as a defining functional characteristic of these peptides.

The ability of the chicken GRF and PACAP peptides to stimulate the release of GH from chicken pituitary cells may readily be confirmed using the procedure described by Perez et al. (1987, incorporated herein by reference). The assay procedure described by Perez et al. (1987) may also be
35 used to determine whether variant forms of the chicken GRF and PACAP peptides, produced as described in Section V below, retain the ability to stimulate GH release.

IV. Preferred method for making GRF/PACAP genes and cDNAs

The foregoing discussion describes the original means by which the chicken GRF/PACAP gene was obtained and also provides the nucleotide sequence of this gene and of cDNAs produced from this gene. With the provision of this sequence information, the polymerase chain reaction (PCR) may now be utilized in a more direct and simple method for producing the GRF/PACAP gene and the disclosed cDNA sequences.

To amplify the cDNA sequences, total RNA is extracted from chicken brain cells as described above. The extracted RNA is then used as a template for performing the reverse transcription-polymerase chain reaction (RT-PCR) amplification of cDNA. Methods and conditions for RT-PCR are described above and in Kawasaki et al. (1990). The selection of PCR primers will be made according to the portions of the cDNA which are to be amplified. Primers may be chosen to amplify small segments of a cDNA or the entire cDNA molecule. Variations in amplification conditions may be required to accommodate primers of differing lengths; such considerations are well known in the art and are discussed in Innis et al. (1990). For example, the open reading frame of the chicken GRF cDNA molecule may be amplified using the following combination of primers:

primer 1 5' CACGCCGATGGGATCTTCAGCAAA 3' (Seq. I.D. No. 17)

primer 2 5' CCCGACCCGCTTGGCCATCAGGGA 3' (Seq. I.D. No. 18)

These primers are illustrative only; it will be appreciated by one skilled in the art that many different primers may be derived from the provided cDNA sequence in order to amplify particular regions of the cDNAs encoding GRF, PACAP or the GRF/PACAP precursor.

Alternatively, the gene sequence encoding the GRF/PACAP precursor polypeptide (i.e. the genomic sequence including introns) or pieces thereof may be obtained by amplification using primers based on the presented gene sequence and genomic chicken DNA as a template.

V. Production of GRF/PACAP sequence variants

It will be apparent to one skilled in the art that the biochemical activity of the chicken GRF and PACAP peptides may be retained even though minor variations are made to the nucleotide sequences encoding them. Thus, a nucleic acid sequence could be designed that encodes for the chicken GRF peptide, but which differs by reason of the redundancy of the genetic code, from the exact GRF cDNA sequence disclosed herein. Therefore, the degeneracy of the genetic code further widens the scope of the present invention as it enables major variations in the nucleotide sequence of a DNA molecule while maintaining the amino acid sequence of the encoded protein.

For example, the seventh amino acid residue in the chicken GRF peptide is serine. This is encoded in the GRF gene by the nucleotide codon triplet AGC. Because of the degeneracy of the genetic code, five other nucleotide codon triplets—TCT, TCA, TCG, TCC, and AGT—also code for

serine. Accordingly, the nucleotide sequence of the GRF gene or cDNA could be changed at this position to any one of these five codons without affecting the amino acid composition of the encoded GRF peptide or the functional characteristics of the peptide. The genetic code and variations in nucleotide codons for particular amino acids is presented in Tables 1 and 2. Based upon the
5 degeneracy of the genetic code, variant DNA molecules may be derived from the DNA sequences disclosed herein using standard DNA mutagenesis techniques, or by direct chemical synthesis of DNA sequences.

TABLE 1
The Genetic Code

5	First Position (5' end)		Second Position				Third Position (3' end)	
			T	C	A	G		
10	T		Phe	Ser	Tyr	Cys		T
			Phe	Ser	Tyr	Cys		C
			Leu	Ser	Stop (och)	Stop		A
			Leu	Ser	Stop (amb)	Trp		G
15	C		Leu	Pro	His	Arg		T
			Leu	Pro	His	Arg		C
			Leu	Pro	Gln	Arg		A
			Leu	Pro	Gln	Arg		G
20	A		Ile	Thr	Asn	Ser		T
			Ile	Thr	Asn	Ser		C
			Ile	Thr	Lys	Arg		A
			Met	Thr	Lys	Arg		G
25	G		Val	Ala	Asp	Gly		T
			Val	Ala	Asp	Gly		C
			Val	Ala	Glu	Gly		A
			Val (Met)	Ala	Glu	Gly		G

35 "Stop (och)" stands for the ochre termination triplet, and "Stop (amb)" for the amber. ATG is the most common initiator codon; GTG usually codes for valine, but it can also code for methionine to initiate an mRNA chain.

TABLE 2

The Degeneracy of the Genetic Code

5	Number of Synonymous Codons	Amino Acid	Total Number of Codons
10	6	Leu, Ser, Arg	18
	4	Gly, Pro, Ala, Val, Thr	20
	3	Ile	3
	2	Phe, Tyr, Cys, His, Gln, Glu, Asn, Asp, Lys	18
15	1	Met, Trp	<u>2</u>
	Total number of codons for amino acids		61
	Number of codons for termination		<u>3</u>
	Total number of codons in genetic code		64

20

Additionally, standard mutagenesis techniques may be used to produce peptides which vary in amino acid sequence from the disclosed GRF and PACAP peptides. Such variant peptides include those with variations in amino acid sequence including minor deletions, additions and

25

substitutions. While the site for introducing an amino acid sequence variation is predetermined, the mutation *per se* need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed protein variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence as described

30

above are well known. In order to maintain the ability of the GRF/PACAP peptides to stimulate GH release, preferred peptide variants will differ by only a small number of amino acids from the GRF and PACAP peptide sequences disclosed herein. Preferably, such variants will be amino acid substitutions of single residues. Substitutional variants are those in which at least one residue in the amino acid sequence has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the following Table 3 when it is desired to finely modulate the characteristics of the protein. Table 3 shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative substitutions.

40

TABLE 3

	Original Residue	Conservative Substitutions
5	Ala	ser
	Arg	lys
	Asn	gln, his
	Asp	glu
10	Cys	ser
	Gln	asn
	Glu	asp
	Gly	pro
	His	asn; gln
15	Ile	leu, val
	Leu	ile; val
	Lys	arg; gln; glu
	Met	leu; ile
	Phe	met; leu; tyr
20	Ser	thr
	Thr	ser
	Trp	tyr
	Tyr	trp; phe
25	Val	ile; leu

Substantial changes in immunological and functional identity are made by selecting substitutions that are less conservative than those in Table 3, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in protein properties will be those in which (a) a hydrophilic residue, e.g., seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g., leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histadyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine.

The present invention thus encompasses not only the precise GRF/PACAP peptides described herein but also peptides which are derived from those disclosed and which retain the ability to stimulate the release of GH from chicken pituitary cells in vitro. Similarly the scope of the invention is not limited to the precise nucleic acid sequences disclosed.

V. Construction of recombinant vectors for expression of GRF/PACAP peptides in heterologous systems

With the provision of the nucleotide sequence for the chicken GRF/PACAP gene and
5 nucleotide sequences encoding the individual chicken GRF and PACAP peptides, this invention
enables the construction of recombinant cloning vectors for expressing any combination of the
GRF/PACAP precursor polypeptide, the GRF peptide or the PACAP peptide (as well as variants on
these sequences, as described in the preceding section). For example, the nucleotide sequence
depicted in Seq. I.D. No. 2 may be selected for expression of the full length cDNA encoding the
10 GRF₁₋₄₆/PACAP₁₋₃₈ precursor polypeptide, whereas the sequence shown in Seq. I.D. No. 12 may be
selected for expression of GRF₁₋₄₆ alone.

The expression of these open reading frames (ORFs) in heterologous cell systems involves the
introduction of the ORF into a vector (such as a plasmid), in such a way that the ORF is operably
linked to regulatory sequences to direct transcription of the ORF. The recombinant vector is
15 introduced into the selected host cell, which is then grown under conditions which support the
expression of the ORF and production of the peptide sequence. Methods for expressing proteins by
recombinant means in compatible prokaryotic or eukaryotic host cells are well known in the art and
are discussed, for example, in Sambrook et al. (1989) and in Ausubel et al. (1987).

The most commonly used prokaryotic hosts are strains of *Escherichia coli*, although other
20 prokaryotes, such as *Bacillus subtilis* or *Pseudomonas* may also be used, as is well known in the art.
For expression in a bacterial host, the selected ORF is ligated into bacterial expression vectors.
Methods for expressing large amounts of protein from a cloned gene introduced into *Escherichia coli*
(*E. coli*) may be utilized for the purification of the peptide. Methods and plasmid vectors for
producing fusion proteins and intact native proteins in bacteria are described in Sambrook et al.
25 (1989) (ch. 17). Such fusion proteins may be made in large amounts, are easy to purify, and can be
used to produce antibodies. Native proteins can be produced in bacteria by placing a strong,
regulated promoter and an efficient ribosome binding site upstream of the cloned gene. If low levels
of protein are produced, additional steps may be taken to increase protein production; if high levels
of protein are produced, purification is relatively easy.

30 Often, proteins expressed at high levels are found in insoluble inclusion bodies. Methods for
extracting proteins from these aggregates are described in ch. 17 of Sambrook et al. (1989). Vector
systems suitable for the expression of *lacZ* fusion genes include the pUR series of vectors (Ruther
et al. (1983)), pEX1-3 (Stanley and Luzio (1984)) and pMR100 (Gray et al. (1982)). Vectors
suitable for the production of intact native proteins include pKC30 (Shimatake and Rosenberg
35 (1981)), pKK177-3 (Amann and Brosius (1985)) and pET-3 (Studier and Moffatt (1986)). Fusion
proteins may be isolated from protein gels, lyophilized, ground into a powder and used as antigen
preparations.

Mammalian or other eukaryotic host cells, such as those of yeast, filamentous fungi, plant,
insect, amphibian or avian species, may also be used for protein expression, as is well known in the

art. Examples of commonly used mammalian host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cells, and WI38, BHK, and COS cell lines, although it will be appreciated by the skilled practitioner that other prokaryotic and eukaryotic cells and cell lines may be appropriate for a variety of purposes, e.g., to provide higher expression, desirable glycosylation patterns, or other features.

For expression in mammalian cells, the ORF sequence may be ligated to heterologous promoters, such as the SV40 promoter in the pSV2 vector (Mulligan and Berg, 1981), and introduced into cells, such as monkey COS-1 cells (Gluzman, 1981), to achieve transient or long-term expression. To achieve this, the ORF or a mini gene (a cDNA with an intron and its own promoter) is introduced into eukaryotic expression vectors by conventional techniques. These vectors are designed to permit the transcription of a cDNA in eukaryotic cells by providing regulatory sequences that initiate and enhance the transcription of the cDNA. Vectors containing the promoter and enhancer regions of the SV40 or long terminal repeat (LTR) of the Rous Sarcoma virus and polyadenylation and splicing signal from SV40 are readily available (Mulligan et al., 1981; Gorman et al., 1982). The level of expression of the cDNA can be manipulated with this type of vector, either by using promoters that have different activities (for example, the baculovirus pAC373 can express cDNAs at high levels in *S. frugiperda* cells (Summers and Smith, 1985)) or by using vectors that contain promoters amenable to modulation, for example, the glucocorticoid-responsive promoter from the mouse mammary tumor virus (Lee et al., 1982).

In addition, some vectors contain selectable markers such as the *gpt* (Mulligan and Berg, 1981) or *neo* (Southern and Berg, 1982) bacterial genes. These selectable markers permit selection of transfected cells that exhibit stable, long-term expression of the vectors (and therefore the introduced ORF). The vectors can be maintained in the cells as episomal, freely replicating entities by using regulatory elements of viruses such as papilloma (Sarver et al., 1981) or Epstein-Barr (Sugden et al., 1985). Alternatively, one can also produce cell lines that have integrated the vector into genomic DNA. Both of these types of cell lines produce the gene product on a continuous basis. One can also produce cell lines that have amplified the number of copies of the vector (and therefore of the ORF as well) to create cell lines that can produce high levels of the gene product (Alt et al., 1978).

The transfer of DNA into eukaryotic, in particular human or other mammalian cells, is now a conventional technique. The vectors are introduced into the recipient cells as pure DNA (transfection) by, for example, precipitation with calcium phosphate (Graham and vander Eb, 1973) or strontium phosphate (Brash et al., 1987), electroporation (Neumann et al., 1982), lipofection (Felgner et al., 1987), DEAB dextran (McCuthan et al., 1968), microinjection (Mueller et al., 1978), protoplast fusion (Schafner, 1980), or pellet guns (Klein et al., 1987). Alternatively, the cDNA can be introduced by infection with virus vectors. Systems are developed that use, for example, retroviruses (Bernstein et al., 1985), adenoviruses (Ahmad et al., 1986), or Herpes virus (Spaete et al., 1982).

This invention encompasses in part, recombinant cloning vectors encoding the GRF/PACAP sequence, or portions thereof. The GRF/PACAP sequence is operatively linked in the vector to an expression control sequence in the recombinant DNA molecule so that the GRF/PACAP polypeptide, or a portion thereof, can be expressed in a host cell. The expression control sequence may be
5 selected from the group consisting of sequences that control the expression of genes of prokaryotic or eukaryotic cells and their viruses and combinations thereof. The expression control sequence may be specifically selected from a wide group of characterized regulatory sequences, including the *lac* system, the *trp* system, the *tac* system, the *trc* system, major operator and promoter regions of phage lambda, the control region of fd coat protein, the early and late promoters of SV40, promoters
10 derived from polyoma, adenovirus, retrovirus, baculovirus and simian virus, the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, the promoter of the yeast alpha-mating factors and combinations thereof.

Another aspect of the present invention is a host cell containing a recombinant vector which encodes the GRF/PACAP precursor polypeptide or the GRF or PACAP peptides.
15

VII. Formulation of purified peptides for administration to poultry

The chicken GRF/PACAP precursor polypeptide or the individual GRF or PACAP peptides may be purified from host cells as described above. Alternatively, these peptides may be chemically
20 synthesized using common peptide synthesis techniques. An exemplary peptide synthesis technique is described in U.S. Patent No. 5,326,860, which is incorporated herein by reference.

Once purified, these peptides may be incorporated into slow-release formulations for administration to chicks. Such formulations include the purified peptide and a biocompatible matrix, such as cholesterol. Slow release formulations may take the form of pellets, which can be
25 administered subcutaneously, or may be preparations suitable for injection. The dosage of peptide administered will vary with the predicted speed of release in the body, but will be in the approximate range of 1 μ g - 100mg for a 2kg chicken. Thus, for example, a pellet for subcutaneous administration may be prepared by combining 30mg of powdered cholesterol with 1mg of the selected peptide and compressing the formulation using a standard pellet maker. The peptides may be
30 pelleted alone or in combination (e.g. pellets may be made using just purified GRF, or with GRF combined with PACAP). Formulation of peptides into slow release preparations may be performed according to standard techniques, or may be performed by a commercial supplier of such materials.

VIII. Production of antibodies to GRF and PACAP

35 Monoclonal antibodies may be produced which bind the chicken GRF/PACAP precursor polypeptide or the individual GRF or PACAP peptides (referred to as the "target peptide"). Optimally, antibodies raised against any of the peptides would specifically detect the target peptide against which they were raised. That is, such antibodies would recognize and bind that peptide and

would not substantially recognize or bind to other proteins found in chicken cells. The determination that an antibody specifically detects a particular peptide is made by any one of a number of standard immunoassay methods; for instance, the Western blotting technique (Sambrook et al., 1989). For example, to determine that a given antibody preparation (such as one produced in a mouse)

5 specifically detects the chicken GRF peptide by Western blotting, total cellular protein is extracted from chicken cells (for example, gonad cells) and electrophoresed on a sodium dodecyl sulfate-polyacrylamide gel. The proteins are then transferred to a membrane (for example, nitrocellulose) by Western blotting, and the antibody preparation is incubated with the membrane. After washing the membrane to remove non-specifically bound antibodies, the presence of specifically bound

10 antibodies is detected by the use of an anti-mouse antibody conjugated to an enzyme such as alkaline phosphatase; application of the substrate 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium results in the production of a dense blue compound by immuno-localized alkaline phosphatase. Antibodies which specifically detect the GRF peptide will, by this technique, be shown to bind to the GRF peptide band (which will be localized at a given position on the gel determined by its molecular

15 weight). Non-specific binding of the antibody to other proteins may occur and may be detectable as a weak signal on the Western blot. The non-specific nature of this binding will be recognized by one skilled in the art by the weak signal obtained on the Western blot relative to the strong primary signal arising from the specific antibody-GRF peptide binding.

Substantially pure target peptide suitable for use as an immunogen is isolated from the

20 transfected or transformed cells as described above. Concentration of the target peptide in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few milligrams per milliliter. Monoclonal antibody to the target peptide can then be prepared as follows:

Monoclonal antibody to epitopes of the target peptide identified and isolated as described can

25 be prepared from murine hybridomas according to the classical method of Kohler and Milstein (1975) or derivative methods thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the target peptide over a period of a few weeks. The mouse is then sacrificed, and the antibody-producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of

30 the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall (1980), and derivative methods thereof. Selected positive clones can be expanded and

35 their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Harlow and Lane (1988).

Monoclonal antibodies raised against the chicken PACAP, GRF or PACAP/GRF precursor peptides are useful in purifying these peptides and in detecting the presence of these peptides using

standard biochemical techniques (such as radioimmunoassay, RIA). For example, the antibodies may be used to quantify levels of PACAP or GRF in poultry to which peptide pellets have been administered.

5 **IX. Introduction of GRF/PACAP gene into poultry**

The present invention also facilitates the production of transgenic poultry, expressing elevated levels of GRF and/or PACAP. A vector expressing the desired peptide may be produced as described in Section V above. It may be desirable to produce a construct expressing the GRF/PACAP polypeptide (or the individual GRF or PACAP polypeptides) under the control of the
10 native GRF/PACAP gene promoter, such that the introduced construct expresses the encoded peptide in the same cells and at the same developmental stages as the native peptide is expressed. This may be achieved by operably linking the 5' promoter region of the GRF/PACAP gene (identified as nucleotide numbers 1 to 3074 of Seq. I.D. No. 1) to the selected ORF. While nucleotides 1 to 3074 are known to include regions controlling the expression of the native GRF/PACAP gene, one of skill
15 in the art will also recognize that less than this entire sequence may provide satisfactory regulation of gene expression. Similarly all or part of the nucleotide sequence located 3' of the native GRF/PACAP gene (represented as nucleotide numbers 6201 to 6529 of Seq. I.D. No. 1) may be operably linked to the 3' end of the selected ORF.

Higher or constitutive levels of GRF or PACAP expression may be obtained by using
20 GRF/PACAP constructs in which the open reading frame is operably linked to a promoter known to direct high level or constitutive expression of downstream gene sequences. Promoter sequences specific for particular tissues (e.g. brain or gonads) or particular developmental stages may also be employed.

These recombinant vectors can then be introduced into chickens. Standard methods of
25 producing transgenic fish are not suitable for use in chickens, in part because chicken ova are nearly impossible to obtain as they are fertilized inside the hen and begin to divide rapidly long before they are laid as eggs. Recently, new approaches have been developed, including embryonic stem cell methods (Pain et al., 1996) and primordial germ cell (PGC) isolation (Chang et al., 1992). PGCs are the precursors to ova and sperm; they are formed in the hypoblast, then move through the blood
30 to the genital ridge where they settle and remain in the gonads. PGCs may thus be found in the blood of chicken embryos, and may be separated from the blood cells using a Ficoll gradient. Gene constructs may be introduced into the PGCs using a lipid carrier and the injected PGCs injected into host embryos. The host embryos are then incubated, hatched and allowed to mature to reproductive age. These chickens will have extra copies of the gene only in their eggs and sperm., and may be
35 bred conventionally to produce chicks which have the introduced genetic construct in all of their cells (the presence of the construct can readily be detected using standard PCR techniques). Successful transfer of PGCs from one chicken to another has already been achieved with a hatch rate of 18-30% (Naito et al., 1994).

Accordingly, the present invention includes recombinant DNA molecules that include sequences encoding chicken GRF or PACAP peptides or a GRF/PACAP precursor polypeptide, as well as transgenic non-human animals wherein the genome of these animals includes such a recombinant DNA molecule.

5

X. Cloning of related genes from other species

This invention provides the nucleotide sequence of the chicken GRF/PACAP gene, as well as regulatory sequences associated with this gene. These nucleotide sequences may now be used to obtain corresponding and related sequences from other species. For example, the chicken
10 GRF/PACAP gene sequence may be used as a hybridization probe to isolate corresponding neuropeptide genes from other avian species, such as turkey. Related avian neuropeptide genes may alternatively be obtained using primers derived from the sequences provided herein, in conjunction with standard gene amplification techniques. Hybridization probes and amplification primers useful in such techniques and derived from the disclosed nucleotide sequences are part of the present
15 invention.

By way of example, related avian neuropeptide genes may be obtained by creating a library of avian cDNA or genomic DNA in a plasmid, bacteriophage or phagemid vector and screening this library with a hybridization probe using standard colony hybridization techniques. The hybridization probe consists of an oligonucleotide derived from the chicken GRF/PACAP gene sequence labeled
20 with a suitable marker to enable detection of hybridizing clones. Suitable markers include radiolabeled, such as P-32 and non-radioactive markers, such as biotin. Methods for constructing suitable libraries, production and labelling of oligonucleotide probes and colony hybridization are standard laboratory procedures and are described in standard laboratory manuals such as Sambrook et al. (1989) and Ausubel et al. (1987).

25 Having identified a clone that hybridizes with the oligonucleotide, the clone is sequenced using standard methods such as described in Chapter 13 of Sambrook et al. (1989). Determination of the translation initiation point of the DNA sequence enables the open reading frame of the cDNA to be determined.

An alternative approach to cloning genes homologous to the disclosed chicken nucleotide
30 sequences is the use of the polymerase chain reaction (PCR). In particular, the inverse polymerase chain reaction (IPCR) is useful to isolate DNA sequences flanking a known sequence. Methods for amplification of flanking sequences by IPCR are described in Chapter 27 of Innis et al. (1990).

Accordingly, within the scope of this invention are small DNA molecules which are derived from the disclosed chicken nucleotide sequence. Such small DNA molecules include
35 oligonucleotides suitable for use as hybridization probes or polymerase chain reaction (PCR) primers. For use in gene amplification techniques, these oligonucleotides will preferably comprise a contiguous stretch of at least 10-15 nucleotides of the chicken sequences shown in Seq. I.D. No. 1 or the salmon sequence shown in Seq. I.D. Nos. 8 or 9. For use as hybridization probes, these

oligonucleotides will preferably comprise a contiguous stretch of at least 20-30 nucleotides of these sequences.

Also encompassed in the present invention are nucleotide sequences which are homologous to the chicken GRF/PACAP precursor polypeptide gene and which hybridize to this sequence, or a fragment thereof, under stringent hybridization conditions. Hybridization conditions resulting in particular degrees of stringency will vary depending upon the nature of the hybridization method of choice and the composition and length of the hybridizing DNA used. Generally, the temperature of hybridization and the ionic strength (especially the Na^+ concentration) of the hybridization buffer will determine the stringency of hybridization. Calculations regarding hybridization conditions required for attaining particular degrees of stringency are discussed by Sambrook et al. (1989), chapters 9 and 11, herein incorporated by reference. By way of illustration only, a hybridization experiment may be performed by hybridization of a DNA molecule to a target DNA molecule which has been electrophoresed in an agarose gel and transferred to a nitrocellulose membrane by Southern blotting (Southern, 1975), a technique well known in the art and described in (Sambrook et al., 1989). Hybridization with a target probe labeled with [^{32}P]-dCTP is generally carried out in a solution of high ionic strength such as 6xSSC at a temperature that is 20-25°C below the melting temperature, T_m , described below. For such Southern hybridization experiments where the target DNA molecule on the Southern blot contains 10 ng of DNA or more, hybridization is typically carried out for 6-8 hours using 1-2 ng/ml radiolabeled probe (of specific activity equal to 10^9 CPM/ μg or greater). Following hybridization, the nitrocellulose filter is washed to remove background hybridization. The washing conditions should be as stringent as possible to remove background hybridization but to retain a specific hybridization signal. The term T_m represents the temperature above which, under the prevailing ionic conditions, the radiolabeled probe molecule will not hybridize to its target DNA molecule. The T_m of such a hybrid molecule may be estimated from the following equation (Bolton and McCarthy, 1962):

$$T_m = 81.5^\circ\text{C} - 16.6(\log_{10}[\text{Na}^+]) + 0.41(\% \text{G+C}) - 0.63(\% \text{ formamide}) - (600/l)$$

Where l = the length of the hybrid in base pairs.

This equation is valid for concentrations of Na^+ in the range of 0.01 M to 0.4 M, and it is less accurate for calculations of T_m in solutions of higher $[\text{Na}^+]$. The equation is also primarily valid for DNAs whose G+C content is in the range of 30% to 75%, and it applies to hybrids greater than 100 nucleotides in length (the behavior of oligonucleotide probes is described in detail in Ch. 11 of Sambrook et al., 1989).

Thus, by way of example, for a 150 base pair DNA probe derived the open reading frame of the chicken GRF/PACAP precursor polypeptide gene (with a hypothetical %GC = 45%), a calculation of hybridization conditions required to give particular stringencies may be made as follows:

For this example, it is assumed that the filter will be washed in 0.3 xSSC solution following hybridization, thereby

$$[\text{Na}^+] = 0.045\text{M}$$

$$\%GC = 45\%$$

5 Formamide concentration = 0

$$l = 150 \text{ base pairs}$$

$$T_m = 81.5 - 16(\log_{10}[\text{Na}^+]) + (0.41 \times 45) \frac{(600)}{(150)}$$

$$\text{and so } T_m = 74.4^\circ\text{C}.$$

10 The T_m of double-stranded DNA decreases by 1-1.5°C with every 1% decrease in homology (Bonner et al., 1973). Therefore, for this given example, washing the filter in 0.3 xSSC at 59.4-64.4°C will produce a stringency of hybridization equivalent to 90%; that is, oligonucleotides with more than 10% sequence variation relative to the target sequence will not hybridize (such hybridization conditions may be referred to as "conditions of 90% stringency"). Alternatively, washing the hybridized filter in 0.3 xSSC at a temperature of 65.4-68.4°C will yield a hybridization
15 stringency of 94% (conditions of 94% stringency); that is, oligonucleotides with more than 6% sequence variation relative to the target sequence will not hybridize. The above example is given entirely by way of theoretical illustration. One skilled in the art will appreciate that other hybridization techniques may be utilized and that variations in experimental conditions will necessitate alternative calculations for stringency.

20 The present inventions encompasses nucleic acid molecules which hybridize to the specific nucleic acid molecules presented in the accompanying sequence listing under conditions of high stringency. In preferred embodiments of the present invention, stringent conditions are those under which DNA molecules with more than 25% sequence variation (also termed "mismatch") will not hybridize. Such hybridization conditions thus represent conditions of 75% stringency. In a more
25 preferred embodiment, stringent conditions are those under which DNA molecules with more than 10% mismatch will not hybridize (conditions of 90% stringency).

References

- Ahmad et al. (1986), J. Virol. 57:267.
- 5 Alt et al. (1978), J. Biol. Chem. 253:1357.
- Amann and Brosius (1985), Gene 40:183.
- Arimura, A. (1992), Reg. Pept., 37:287-304.
- 10 Ausubel et al. (1987), Current Protocols in Molecular Biology, ed. Greene Publishing and Wiley-Interscience: New York (with periodic updates).
- Bernstein et al. (1985), Gen. Engr'g 7:235.
- 15 Birnboim, M. (1983), Methods Enzymol., 100: 243-255.
- Bolton and McCarthy (1962), Proc. Natl. Acad. Sci. USA 48:1390.
- 20 Bonner et al. (1973), J. Mol. Biol. 81:123.
- Brash et al. (1987), Mol. Cell Biol. 7:2013.
- Campbell, R.M. and Scanes, C.G. (1992), Growth Reg., 2:175-191.
- 25 Chang et al. (1992), Cell Biology International Reports 16:853-857.
- Chomczynski, P. and Sacchi, N. (1987), Anal. Biochem., 162:156-159.
- 30 Culler, M.D. and Paschall, C.S. (1991), Endocrinology, 129:2260-2262.
- Denver, R.J. and Licht, P. (1989), J. Exp. Zool., 251:306-315.
- Denver, R.J. and Licht, P. (1991), Comp. Biochem. Physiol., 100:603-606.
- 35 DiCicco-Bloom, E.M. (1994), Pituitary Adenylate Cyclase Activating Polypeptide, Program of the 24th Annual Meeting of the Society of Neuroscience, Miami Beach, Florida, p289. (abstract).
- Dirksen et al. (1994), J. Biol. Chem., 269:6431-6436.
- 40 Felgner et al. (1987), Proc. Natl. Acad. Sci USA 84:7413.
- Frohman, M.A. (1988), Proc. Natl. Acad. Sci. (USA), 8:8998-9002.
- 45 Giusti et al. (1986), J. Endocrinol. Invest., 9:497-501.
- Gluzman (1981), Cell 23:175-182.
- Gorman et al. (1982), Proc. Natl. Acad. Sci USA 78:6771-6781.
- 50 Graham and vander Eb (1973), Virology 52:466.
- Gray et al. (1982), Proc. Natl. Acad. Sci. USA 79:6598.
- 55 Green, M.R. (1991), Annu. Rev. Cell Biol. 7:559-599.

- Guo et al. (1991), Genes and Devel., 5:2096-2107.
- Hannibal, J. and Fahrenkrug, J. (1995), Reg. Pept., 55:111-115.
- 5 Harlow and Lane (1988). Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, New York.
- Hart, G.R., Gowing, H. and Burrin, J.M. (1992), J. Endocrinol., 134:33-41.
- 10 Harvey, S. (1990), J. Endocrinol., 125:345-358.
- Huh, G.S. and Hynes, R.O. (1994), Genes and Devel., 8:1561-1574.
- Kawasaki et al. (1990). In PCR Protocols, A Guide to Methods and Applications, Innis et al. (eds.), 21-27, Academic Press, Inc., San Diego, California.
- 15 Kentori, S. and Vernadakis, A. (1990), Brain Res., 512:297-303.
- Klein et al. (1987), Nature 327:70.
- 20 Kohler and Milstein (1975), Nature 256:495.
- Lee et al. (1982), Nature 294:228.
- 25 Ling et al. (1984), Biochem. Biophys. Res. Commun., 123:854-861.
- Luo, D. and McKeown, B.A. (1989), Experimentia, 45:577-580.
- Luo et al. (1990), Gen. Comp. Endocrinol., 80:288-298.
- 30 Malagon et al. (1991), Gen. Comp. Endocrinol., 84:461-469.
- McCuthan et al. (1968), J. Natl Cancer Inst. 41:351.
- 35 McRory et al. (1995), Mol. Cell Endocrinol., 108:169-177.
- Moretti et al. (1990), Endocrinology, 127:2117-2126.
- Mueller et al. (1978), Cell 15:579.
- 40 Mulligan and Berg (1981), Proc. Natl. Acad. Sci. USA 78:2072-2076.
- Mullis et al. (1986), Cold Spring Harbor Symp. Quant. Biol. 51:263-273.
- 45 Murakami et al. (1995), Reg. Pept., 56:35-40.
- Naito et al. (1994), Molecular Reproduction and Development 39:153-161.
- Neumann et al. (1982), EMBO J 1:841.
- 50 Padgett et al. (1986), , Ann. Rev. Biochem., 55:1119-1150.
- Pain et al. (1996), Development 122:2339-2348.
- 55 Parker et al. (1993), Eur. J. Biochem., 215:439-448.

- Patten, B.M. (1964), In: Foundations of Embryology, pp225-264. McGraw-Hill, Toronto.
- Perez, F.M., Malamed, S. and Scanes, C.G. (1987), Gen. Comp. Endocrinol., 65:408-414.
- 5 Pesce et al. (1996), Development, 122:215-221.
- Peter et al. (1984), J. Exp. Zool., 231:161-163.
- Porter et al. (1995), Endocrinology, 136:1850-1856.
- 10 Propato-Mussafiri et al. (1992), J. Endocrinol., 132:107-113.
- Rawlings, S.R. and Hezareh, M. (1996), Endocrine Rev., 17:4-29.
- 15 Rivier et al. (1982), Nature (London), 300:276-278.
- Robberecht et al. (1994), Peptides, 15:661-665.
- Ruther et al. (1983), EMBO J. 2:1791.
- 20 Sambrook J., Fritsch, B.F., and Maniatis, T. (1989), Molecular Cloning, a Laboratory Manual, 2nd ed., Cold Spring Harbor: Cold Spring Harbor Laboratory Press.
- Sanger, F., Nicklen, S. and Coulson, A.R. (1977), Proc. Natl. Acad. Sci. (USA), 74:5463-5467.
- 25 Sarver et al. (1981). Mol. Cell Biol. 1:486.
- Scanes, C.G. and Harvey, S. (1984), Gen. Comp. Endocrinol., 56:198-203.
- 30 Schafner (1980). Proc. Natl. Acad. Sci. USA 77:2163-2167.
- Seungkwon et al. (1995), Endocrinology 136:2602-2610.
- Sherwood et al. (1994), In: Fish Physiology, N.M. Sherwood and C. Hew (eds), 13:3-66 Academic Press, Orlando.
- 35 Shimatake and Rosenberg (1981), Nature 292:128.
- Shuto et al. (1994), Program of the 24th Annual Meeting of the Society of Neuroscience, Miami Beach, Florida, 1994, p870 (abstract).
- 40 Southern, B. (1975), J. Mol. Biol., 98:503.
- Southern and Berg (1982), J. Mol. Appl. Genet. 1:327-341.
- 45 Spaete et al. (1982), Cell 30:295.
- Stanley and Luzio (1984), EMBO J. 3:1429.
- 50 Studiar and Moffatt (1986), J. Mol. Biol. 189:113.
- Sugden et al. (1985), Mol. Cell Biol. 5:410.
- 55 Summers and Smith (1985), In Genetically Altered Viruses and the Environment, Fields et al. (Eds.) 22:319-328, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.

- Tacke, R. and Goridis, C. (1991), Genes and Devel., 5:1416-1429.
- Talbot et al. (1995), J. Mol. Endocrinol., 15:81-91.
- 5 Vale et al. (1983), Endocrinology, 112:1553-1555.
- Vaughan et al. (1992), Neuroendocrinology, 56:539-549.
- Watakabe, A., Tanaka, K. and Shimura, Y. (1993), Genes and Devel., 7:407-418.
- 10 Xu, R., Teng, J. and Cooper, T.A. (1993), Mol. Cell Biol., 13:3660-3574.
- Zahler et al. (1992), SR Proteins: Genes and Devel., 6:837-847.

SEQUENCE LISTING

- (1) GENERAL INFORMATION
- (1) APPLICANT: SHERWOOD ET AL.
- 5 (ii) TITLE OF INVENTION: CHICKEN NEUROPEPTIDE GENE USEFUL
FOR IMPROVED POULTRY PRODUCTION
- (iii) NUMBER OF SEQUENCES: 20
- 10 (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: Klarquist Sparkman Campbell Leigh &
Whinston, LLP
- 15 (B) STREET: One World Trade Center
121 S.W. Salmon Street
Suite 1600
- (C) CITY: Portland
- (D) STATE: Oregon
- (E) COUNTRY: United States of America
- 20 (F) ZIP: 97204-2988
- (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: Disk, 3-1/2 inch
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: MS DOS
- 25 (D) SOFTWARE: WordPerfect 7.0 & ASCII
- (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER: 08/789,329
- (B) FILING DATE: 01/23/97
- (C) CLASSIFICATION:
- 30 (vii) PRIOR APPLICATION DATA:
- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: Earp, David J.
- 35 (B) REGISTRATION NUMBER: 41,401
- (C) REFERENCE/DOCKET NUMBER: 2847-46468/DJE
- (ix) TELECOMMUNICATION INFORMATION:
- (A) TELEPHONE: (503) 226-7391
- (B) TELEFAX: (503) 228-9446
- 40 (2) INFORMATION FOR SEQ ID NO: 1:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6529 bp
- (B) TYPE: nucleic acid
- 45 (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
- tttttccac agtaacaatt ctggttgaaa taataaaaag gattattttt tggatatgtt 60
aaatactgaa attttgattt ttggactctg gtgtaatttt ttttcctggg gggtccttgc 120

taccaagtgt aagtatatta ttgacttttg aatccgatgg gcttttagaa aaaggagtta 180
 atttatatat ttgggggtgtt tctctgagat atttactcc atgaaaacag atttcttcta 240
 agcctcagca agacttgaga tcaccctaaa atgtatgcat tgttcttggt ttccataagc 300
 atccttgagt tagccttctc tgatgtttaa atgtaggag gtgaccagaa tttgctctga 360
 5 gacacaatga caaggaaggt atgagcacag aattacagaa agggaaaaaa tacatattct 420
 actcagataa aataaagctg ttgtcaataa catgatttat tcaaaactcct catctatggg 480
 aagtaagtaa ctctgttctg aatatatcta ctgtctataa ctcgacagat cagttctgca 540
 gttegtgttc tggaccaggg attgcgtggg gtgcactggg cacaaccaca tctttgattt 600
 ctttcttcaa attctcagt tagaatgttt ttatattacc tcaaaagctt gagatacaag 660
 10 gtaaatacag gggatatagt ttaaagttct gtgtaagtgt ggggaaaaata tctccacatc 720
 acagagtttg gagaaaaggc aatctgcatt tgctgatgtg cacatacaaa tttctatggg 780
 ttcttcattgc tacattaaaa gcttcacaag gaatctttcc ccaacttcca gcgttgatta 840
 gtgaacagcg ctattagtca ttacactcaa tatacttggg gtcccttctt gattttcctg 900
 aagaagcagc agtagggaga gctgaatcac gagttttcct catatttttc ttaatgaaaa 960
 15 atcatttgca ctgctgttct ggaacacagc accaggtaat gtcaacacat tagaaagatg 1020
 acaaaagttc ccaatcacgg gtctcgagtc agtcccttt agtgagggtta attgagcttc 1080
 caattcgaat atagttagtc gtattacgcg cgctcactgg ccgtcgtttt acaacgctcg 1140
 gactgggaaa cctggcggtt acccaactta atcgcttgc agcacatccc ctttccgcca 1200
 gctggcgat agcgaagagg cccgcaccga tcgccaacc caacagttgc gcagcctgaa 1260
 20 tggcgaatgg gacgcgcct gtagcgctca ttaagcgcg cggaagctc taaatcgggg 1320
 ggctccttta ggttccgatt agtgctttac ggcacctga ccccaaaaaa acttgattag 1380
 ggtgatggtt cagtagtggt cctacgccct gatagacggt ttttttcgcc ctttgacgtt 1440
 ggagtccacg ttttttaata gtggactctt gttccaaact ggaacaacac tcaaccctat 1500
 ctccgtctat tcttttgatt tataagggat tttgccgatt tcggcctatt ggttaaaaaa 1560
 25 tgagctgatt taacaaaaat ttaacgcgaa ttttaacaaa atattaacgc ttacaattta 1620
 ggtggcactt ttcggggaaa tgtgcgcggg gccctattg tttatttttc taatacattc 1680
 aaatatgtat ccgctcatga gacaataacc ctgataaatg cttcagtaat attgcataat 1740
 ttacaatggc gaagaaaact atacatcccc cccagacaa tctagggtgt ctctctacct 1800
 ccaagagatc gatgtcaaga gatcgcttag aacatcgat tatctcttcc ccggagaggc 1860
 30 aagtatacaa gaagaattaa ctcaatgtga agaatacatc ttagagggat tatacagatga 1920
 ctctaccct ctgatctggg cttcttctca tcgcgcactc tgagagaagc aaccgagaat 1980
 tcagcccttt ataagagtgt gatttttagcc aaaatgaatt ccatcccacc catcccaaaa 2040
 gtcggatact gtgggttcag taccgtgcat cgatcgatcg atggagcatg catcgatgct 2100
 agcatgcatg ctgctagct attctttatt ttttttttg tatgctagat aaagctttcg 2160
 35 gtttgattt tacgacgtct tgcatacgca ctgaacttga cattgacatc tctttgcaca 2220
 cctaaactaa aaataattaa gccattact catcctcaga gaaccaagggt aatcaaggag 2280
 tctttgcaac tgagcaaaag ctgtccttca gaaggaatct ttcccaact tccagcgttg 2340
 attagtgaac agcgtatta gtcattacac tcaatatact tgggtgtcctt ccttgatttt 2400
 cctgggggaa gaagcaggag taggggagaa ctgaatcacg agttttctc atatttttct 2460
 40 taatgaaaaa gctcattaat ggatgctgtt ctggaacaca ggaccaggta atgtcaaac 2520
 attaaaaaga tgacaaaagt tcccaaggac ggatctcgag tcgactcaca accagagggt 2580
 gccaggacat tgcaggactg aactttctct ttcaaccctc caatctattt tgagctctcc 2640
 agaggaaatg ggatttgtcc acagtaacca ctgtggctga gataataaac tgcattactc 2700
 tctggatatg tttaaaatac tgagacttta atatgatttt tgcactctag tgtaatttct 2760
 45 tttccgatgc tagcatcgat gctagctggg cgggttatca tgcccaacgt cgtagctgtg 2820

ataaaaaaaa atgacgtctg tgctgtagct gatcgatgca tgcataaata aaaaaagtgt 2880
 gtgtgtgact ccgtgctgat gctgtgcttg gggctttctt gctaccaagt gtaagtgtga 2940
 tgtgagttgc agcttcgcat ttgcagactc ctatgggcaa ttttttagaaa aaggagttaa 3000
 tttaatataa atttggggtg tttctctgaa gatatttcac tccacagtga aaacagattt 3060
 5 cttctaagcc tcagGCGAAT ATTGACAGCC CCCCTTTTTT TTCCTTTATT TGTCGAGTCG 3120
 ATTCCCTAAC CACCCAACAA CTCTCTGCGC TTCTGCGCCT TCTTCATCCT TGCCCAGCGG 3180
 AAAAGCCGGG AGCCCTTTGA CTCTTCGGC CGCAACTTGG GGAGATAGCT CTATTTTCC 3240
 CCCCTCCTCT CTGGGGTTTT TCTCCTTTTT CCTCTCTCCC TTCCCTTCC GCAGCCACAC 3300
 GCTCTCAGTG CCGGGTGTCA CAggtgtgtaa atcaagactt gaggatcacc ctaagggtga 3360
 10 tgccttggtc ttgtttcagt agtacagagt gaatgaaaa ccactggata agcatgttga 3420
 gttagcttct ctgatttggg tgtaggagtg acaagaattt gctctgagac acagGTTTCA 3480
 TGAGTGGCAA TGTGTATAAA ACGCTCTTAA CCCTCCTGGT CTATGGATTA ATAATGCATT 3540
 GCAACGTCTA CTGCTCACCC GACCGTTGGA CTCCAGTACC CGGCGCTAAG gtgagtctgt 3600
 cagtgaata tgctactctc acatcaggct ctgtgtcaca agtcatctgc caatctatca 3660
 15 gtgctgttaa gtggaattac tgagtaggtg cttggccac caaggctgag aatccagctg 3720
 cagtggatca gccatctac cccctgcaca cacgtgtgga ttcaccccat cccctgcca 3780
 ccctgccacc ccatgctgcc ccacacagtc cctataggga tgaggctctc ccaccagggg 3840
 actgtgctgc caccatccga cactcctcta gcaaccaagc aaccaacca attggtgttt 3900
 tgtaataggc tgcagtctgt tttgtaatag gaaatataga tgattctact ttattctccc 3960
 20 tggctcctgc aacgataaga atgttetaat tcattattaa tttgttcctt ctatttctgg 4020
 taattctaaa ctatggataa cctcagtgat gccattagca atacctcgag gactacgaga 4080
 tggggtttac gtttctggac atggggtcgt ggaggcagcc cctctggcca taagggtggt 4140
 ccctaaacc tgacacattt gggacataac tggacttgc cattcacact gggttacagt 4200
 gttgtgacaa acaacctgga gcacagagaa atcgtggcta gttatttgc tgggtgaaat 4260
 25 gattgtagct cagcagcact ccgtgaaact tgcttattcc atctgtttat ggatttactc 4320
 tccactgagc acaaatggaa atgagggtgg gagcagggcc tagggtcttc tgccagcacc 4380
 aggggtgac tcctcccatg ggcctgcca ggcctgcagt gacattctgc aagctagctg 4440
 gtgttagtgt agaggagggg ccatggaaca ttacatctcc aaaaggtaact ttttcgatct 4500
 tggattgcac tttcataatt tatttctcta ttcaaatgat tgattgaaga acagtgtgta 4560
 30 aaaaatctag ggaatgata tttttattct tctgtaaaat acaacttat ctgggtgaaa 4620
 aatgggagat tacaagtata tctgttggtc tctggaggaa attagctgca acccgtgtgg 4680
 catgatggca cctccttgty cagccaagcc ttctgttagg ctttccgttc atctagaaag 4740
 tgctctcctt gcctttgtgt tttgatagga atgactctc ctttgctact cttatttcca 4800
 ctgtatgggg ttaagaagac tcgtcacgct gggctgagca ctggagcgag ctgctccgt 4860
 35 cccgcacggt cccgcggcgg ggacggggt ggggacgtcc ggctgagccc gcccgtgctt 4920
 accgcagCTG GAGGAGGAGG TATACGACGA GGACGGGAAT ACCCTACAGG ACTTCGCACT 4980
 ACGAGCAGGA GCCCTGGGG GTGGCGGGCC GCGCCCGCGC TGGGGCAGGT GTACGGCGCT 5040
 GTACTACCCG CCGGGAAGA Ggtgacagag gggcgccgga tagggccggg gggggagggg 5100
 ggggaatggga aacctaaagg ccccgggggg agggcgggaa atatcgtaat tccgccccac 5160
 40 ctgggctgcy cgagcggggg aggggggtgg ggaggaggg cgcctcgggg atgggcgctg 5220
 acgggcccgtg ccccggcagG CACGCCGATG GGATCTTCAG CAAAGCCTAC AGGAAACTCC 5280
 TGGGCCAGCT GTCCCAAGA AATTACCTGC ACTCCCTGAT GGCCAAGCGG GTCGGgtaag 5340
 ggctgcggcg ggacgggagc gaacaaagcg cggcgcgcgg cggccggggc ggggcggccc 5400
 attctccccg cgggtgctctg ccggaacgag agaggcgggc gcaaccgggg ctcggcgtcc 5460
 45 ctcccgcggy gcagccccgg gtggtgccat cggagcgaa ccccccggy aacgcgatgc 5520

ataatgcatg gggggggggg ggggagacgt ctcgctccgg cccggccccg ccctttgtct 5580
 gccgggagat gcggggccgg ggcgggggtt agggccgggg ttgggggttg ggttgggtta 5640
 gggccggggtt gggtcggggc cgggagggcc cctcctgatg gttgtgtcct tctcgggtgct 5700
 ttgcagCGGT GCCAGCAGCG GCCTGGGGGA CGAGGCGGAA CCGCTCAGCA AGCGCCACAT 5760
 5 AGACGGCATC TTCACGGACA GCTACAGCCG CTACCGGAAA CAAATGGCTG TCAAGAAATA 5820
 CTTAGCGGCC GTCCTGGGGA AAAGGTATAA ACAAAGAGTT AAAACAAAG GACGCCGAGT 5880
 AGCGTATTTG TAGgatgagc aaccgccgct gccgtgcgta gtcctgagag agagagagag 5940
 agagagagag agattgagag agagagagag agagagagag acccaaccac cccaacccaa 6000
 acaaaagtca tttccaaagt gacggaacga ccgcccgtcc cgtgttcccc aaacatgtat 6060
 10 ttatgtataa gtaagccatt aaatgaataa ttttttgata ataatatggt tttcttttgt 6120
 acgaaagcac agatctactt tgtggacca tcttgagtt atatatgaga tagaatatat 6180
 atatataata ctgctactaa agagcgattc ttcataccaa gctgcaccag gacgagagtt 6240
 cgcttgagct gttagttttt atagaaaaca aatagacgaa aaaaaaaaaa aagacaatca 6300
 ccgcttccaa cagcgctcct atttttgtaa cggaaacgaa aagggcactg tttttattgc 6360
 15 cacgggggag aacacctcag ttctcaccgt gtgcgctgtg atagggaggg ctcacgcagc 6420
 aggggtcccc ccggcctcga tctctctctc tttttcccc accccccct tttttttttt 6480
 tccctttgat tccggtccta tccgtatcag tctcctcag agcgatgag 6529
 (2) INFORMATION FOR SEQ ID NO: 2:
 (i) SEQUENCE CHARACTERISTICS:
 20 (A) LENGTH: 1088 bp
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
 25 gcgaatattg acagcccccc ttttttttcc tttatttgtc gagtcgattc cctaaccacc 60
 caacaactct ctgcgcttct gcgccttctt catccttgcc cagcggaaaa gccgggagcc 120
 ctttgactct ttccggccga acttggggag atagctctat ttttcccccc tctctctctg 180
 ggtttttctc ctttttctc tctcccttct ccttcgcgag ccacacgctc tcagtgcggy 240
 gtgtcacagt ttcATGAGTG GCAATGTGTA TAAACGCTC TTAACCTCC TGGTCTATGG 300
 30 ATTAATAATG CATTGCAACG TCTACTGCTC ACCCGACCGT TGGACTCCAG TACCCGGCGC 360
 TAAGCTGGAG GAGGAGGTAT ACGACGAGGA CGGGAATACC CTACAGGACT TCGCACTACG 420
 AGCAGGAGCC CCTGGGGGTG GCGGGCCGCG CCCGCGCTGG GGCAGGTGTA CGGCGCTGTA 480
 CTACCCGCGG GGAAAGAGGC ACGCCGATGG GATCTTCAGC AAAGCCTACA GGAACTCCT 540
 GGGCCAGCTG TCCGCAAGAA ATTACCTGCA CTCCCTGATG GCCAAGCGGG TCGGCGGTGC 600
 35 CAGCAGCGGC CTGGGGGACG AGGCGGAACC GCTCAGCAAG CGCCACATAG ACGGCATCTT 660
 CACGGACAGC TACAGCCGCT ACCGGAACA AATGGCTGTC AAGAAATACT TAGCGGCCGT 720
 CCTGGGGAAA AGGTATAAAC AAAGAGTTAA AAACAAAGGA CGCCGAGTAG CGTATTTGTA 780
 Ggatgagcaa ccgcccgtgc cgtgcgtagt cctgagagag agagagagag agagagagag 840
 attgagagag agagagagag agagagagac ccaaccaccc caaccacaaac aaaagtcatt 900
 40 tccaaagtga cggaacgacc gccgctcccg tgttccccaa acatgtatgt atgtataagt 960
 aagccattaa atgaataata ttttgataat aatatggttt tcttttgtac gaaagcacag 1020
 atctactttg tggaccaatc cttgagttat atatgagata gaatatatat atataatact 1080
 gctactaa 1088

45 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 aa
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Ser Gly Asn Val Tyr Lys Thr Leu Leu Thr Leu Leu Val Tyr Gly
 1 5 10 15
 Leu Ile Met His Cys Asn Val Tyr Cys Ser Pro Asp Arg Trp Thr Pro
 20 25 30
 Val Pro Gly Ala Lys Leu Glu Glu Glu Val Tyr Asp Glu Asp Gly Asn
 35 40 45
 Thr Leu Gln Asp Phe Ala Leu Arg Ala Gly Ala Pro Gly Gly Gly Gly
 50 55 60
 Pro Arg Pro Arg Trp Gly Arg Cys Thr Ala Leu Tyr Tyr Pro Pro Gly
 65 70 75 80
 Lys Arg His Ala Asp Gly Ile Phe Ser Lys Ala Tyr Arg Lys Leu Leu
 85 90 95
 Gly Gln Leu Ser Ala Arg Asn Tyr Leu His Ser Leu Met Ala Lys Arg
 100 105 110
 Val Gly Gly Ala Ser Ser Gly Leu Gly Asp Glu Ala Glu Pro Leu Ser
 115 120 125
 Lys Arg His Ile Asp Gly Ile Phe Thr Asp Ser Tyr Ser Arg Tyr Arg
 130 135 140
 Lys Gln Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg
 145 150 155 160
 Tyr Lys Gln Arg Val Lys Asn Lys Gly Arg Arg Val Ala Tyr Leu
 165 170 175

40

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 46 aa
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

His Ala Asp Gly Ile Phe Ser Lys Ala Tyr Arg Lys Leu Leu Gly Gln
 1 5 10 15
 Leu Ser Ala Arg Asn Tyr Leu His Ser Leu Met Ala Lys Arg Val Gly
 20 25 30
 Gly Ala Ser Ser Gly Leu Gly Asp Glu Ala Glu Pro Leu Ser
 35 40 45

55

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 aa

- (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

5 His Ile Asp Gly Ile Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gln
 1 5 10 15
 Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Lys
 20 25 30
 10 Gln Arg Val Lys Asn Lys
 35

15

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1079 bp
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

gcgaatattg acagccccc ttttttttcc tttatttgtc gagtcgattc cctaaccacc 60
 caacaactct ctgcgttctt gcgccttctt catccttgcc cagcggaaaa gccgggagcc 120
 25 ctttgactct ttccggccga acttggggag atagctctat ttttcccccc tcctctctgg 180
 ggtttttctc ctttttccct tctccctttc ccttccgcag ccacacgctc tcagtgcggg 240
 gtgtcacagt ttcATGAGTG GCAATGTGTA TAAAACGCTC TTAACCCTCC TGGTCTATGG 300
 ATTAATAATG CATTGCAACG TCTACTGCTC ACCCGACCGT TGGACTCCAG TACCCGGCGC 360
 TAAGCTGGAG GAGGAGGTAT ACGACGAGGA CGGGAATACC CTACAGGACT TCGCACTACG 420
 30 AGCAGGAGCC CCTGGGGGTG GCGGGCCGCG CCCGCGCTGG GGCAGGTGTA CGGCGCTGTA 480
 CTACCCGCCG GGAAAGAGGC ACGCCGATGG GATCTTCAGC AAAGCCTACA GGAAACTCCT 540
 GGGCCAGCTG TCCGCAAGAA ATTACCTGCA CTCCCTGATG GCCAAGCGGG TCGGCAGCGG 600
 CCTGGGGGAC GAGGCGGAAC CGCTCAGCAA GCGCCACATA GACGGCATCT TCACGGACAG 660
 CTACAGCCGC TACCGGAAAC AAATGGCTGT CAAGAAATAC TTAGCGGCCG TCCTGGGGAA 720
 35 AAGGTATAAA CAAAGAGTTA AAAACAAAGG ACGCCGAGTA GCGTATTGT AGgatgagca 780
 accgccgctg ccgtgcgtag tcctgagaga gagagagaga gagagagaga gattgagaga 840
 gagagagaga gagagagaga cccaaccacc ccaaccctaa caaaagtcatt ttccaaagt 900
 acggaacgac cgccgctccc gtgttcccca aacatgtatt tatgtataag taagccatta 960
 aatgaataat attttgataa taatatggtt ttcttttgta cgaaagcaca gatctacttt 1020
 40 gtggaccaat ccttgagtta tatatgagat agaatatata tatataatac tgctactaa 1079

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 172 aa
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Ser Gly Asn Val Tyr Lys Thr Leu Leu Thr Leu Leu Val Tyr Gly
 1 5 10 15
 5 Leu Ile Met His Cys Asn Val Tyr Cys Ser Pro Asp Arg Trp Thr Pro
 20 25 30
 Val Pro Gly Ala Lys Leu Glu Glu Glu Val Tyr Asp Glu Asp Gly Asn
 35 40 45
 10 Thr Leu Gln Asp Phe Ala Leu Arg Ala Gly Ala Pro Gly Gly Gly Gly
 50 55 60
 Pro Arg Pro Arg Trp Gly Arg Cys Thr Ala Leu Tyr Tyr Pro Pro Gly
 65 70 75 80
 15 Lys Arg His Ala Asp Gly Ile Phe Ser Lys Ala Tyr Arg Lys Leu Leu
 85 90 95
 Gly Gln Leu Ser Ala Arg Asn Tyr Leu His Ser Leu Met Ala Lys Arg
 100 105 110
 Val Gly Ser Gly Leu Gly Asp Glu Ala Glu Pro Leu Ser Lys Arg His
 115 120 125
 25 Ile Asp Gly Ile Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gln Met
 130 135 140
 Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Lys Gln
 145 150 155 160
 30 Arg Val Lys Asn Lys Gly Arg Arg Val Ala Tyr Leu
 165 170

35 (2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 43 aa
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

His Ala Asp Gly Ile Phe Ser Lys Ala Tyr Arg Lys Leu Leu Gly Gln
 1 5 10 15

45 Leu Ser Ala Arg Asn Tyr Leu His Ser Leu Met Ala Lys Arg Val Gly
 20 25 30

Ser Gly Leu Gly Asp Glu Ala Glu Pro Leu Ser
 35 40

50

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 992 bp
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

gcgaatattg acagccccc ttttttttcc tttatttgtc gattcgattc cctaaccacc 60
 caacaactct ctgcgcttct ggccttctt catccttgcc cagcggaata gccgggagcc 120

ctttgactct ttcggccgca acttggggag atagctctat ttttcccccc tcctctctgg 180
 ggttttttctc ctttttcttc tctccctttc ccttccgcag ccacacgctc tcagtgccgg 240
 gtgtcacagt ttcATGAGTG GCAATGTGTA TAAAACGCTC TTAACCTCC TGGTCTATGG 300
 ATTAATAATG CATTGCAACG TCTACTGCTC ACCCGACCGT TGGACTCCAG TACCCGGCGC 360
 5 TAAGCTGGAG GAGGAGGTAT ACGACCAGGA CGGGAATACC CTACAGGACT TCGCACTACG 420
 AGCAGGAGCC CCTGGGGGTG GCGGGCCGCG CCCGCGCTGG GGCAGGTGTA CGGCGCTGTA 480
 CTACCCGCCG GGAAAGAGCG GTGCCAGCAG CGGCCTGGGG GACGAGGCGG AACCGCTCAG 540
 CAAGCGCCAC ATAGACGGCA TCTTACGGA CAGCTACAGC CGCTACCGGA AACAAATGGC 600
 TGTCAAGAAA TACTTAGCGG CCGTCTGGG GAAAAGGTAT AAACAAAGAG TTAAAAACAA 660
 10 AGGACGCCGA GTAGCGTATT TGTAGgatga gcaaccgccg ctgccgtgcg tagtctgag 720
 agagagagag agagagagag agagattgag agagagagag agagagagag agacccaacc 780
 accccaaccc aaacaaaagt catttccaaa gtgacggaac gaccgccgct cccgtgttcc 840
 ccaaacatgt atttatgtat aagtaagcca ttaaatgaat aatattttga taataatatg 900
 gttttctttt gtacgaaagc acagatctac tttgtggacc aatccttgag ttatatatga 960
 15 gatagaatat atatatataa tactgctact aa 992

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 143 aa
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

25 Met Ser Gly Asn Val Tyr Lys Thr Leu Leu Thr Leu Leu Val Tyr Gly
 1 5 10 15
 Leu Ile Met His Cys Asn Val Tyr Cys Ser Pro Asp Arg Trp Thr Pro
 20 25 30
 30 Val Pro Gly Ala Lys Leu Glu Glu Glu Val Tyr Asp Glu Asp Gly Asn
 35 40 45
 35 Thr Leu Gln Asp Phe Ala Leu Arg Ala Gly Ala Pro Gly Gly Gly Gly
 50 55 60
 Pro Arg Pro Arg Trp Gly Arg Cys Thr Ala Leu Tyr Tyr Pro Pro Gly
 65 70 75 80
 40 Lys Ser Gly Ala Ser Ser Gly Leu Gly Asp Glu Ala Glu Pro Leu Ser
 85 90 95
 Lys Arg His Ile Asp Gly Ile Phe Thr Asp Ser Tyr Ser Arg Tyr Arg
 100 105 110
 45 Lys Gln Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg
 115 120 125
 50 Tyr Lys Gln Arg Val Lys Asn Lys Gly Arg Arg Val Ala Tyr Leu
 130 135 140

(2) INFORMATION FOR SEQ ID NO:11:

55 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 129bp
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
- | | |
|---|-----|
| CAC GCC GAT GGG ATC TTC AGC AAA GCC TAC AGG AAA CTC CTG GGC CAG | 48 |
| CTG TCC GCA AGA AAT TAC CTG CAC TCC CTG ATG GCC AAG CGG GTC GGC | 96 |
| AGC GGC CTG GGG GAC GAG GCG GAA CCG CTC AGC | 129 |
- 10
- (2) INFORMATION FOR SEQ ID NO:12:
- (i) SEQUENCE CHARACTERISTICS:
- 15 (A) LENGTH: 138bp
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
- | | |
|---|-----|
| CAC GCC GAT GGG ATC TTC AGC AAA GCC TAC AGG AAA CTC CTG GGC CAG | 48 |
| CTG TCC GCA AGA AAT TAC CTG CAC TCC CTG ATG GCC AAG CGG GTC GGC | 96 |
| GGT GCC AGC AGC GGC CTG GGG GAC GAG GCG GAA CCG CTC AGC | 138 |
- 20
- (2) INFORMATION FOR SEQ ID NO:13:
- (i) SEQUENCE CHARACTERISTICS:
- 25 (A) LENGTH: 114bp
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
- | | |
|---|-----|
| CAC ATA GAC GGC ATC TTC ACG GAC AGC TAC AGC CGC TAC CGG AAA CAA | 48 |
| ATG GCT GTC AAG AAA TAC TTA GCG GCC GTC CTG GGG AAA AGG TAT AAA | 96 |
| CAA AGA GTT AAA AAC AAA | 114 |
- 35
- (2) INFORMATION FOR SEQ ID NO:14:
- (i) SEQUENCE CHARACTERISTICS:
- 40 (A) LENGTH: 27bp
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
- | | |
|------------------------------|----|
| CATGTTTGA CAGAACACAA GTGAGCG | 27 |
|------------------------------|----|
- 45
- (2) INFORMATION FOR SEQ ID NO:15:
- 50 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 26bp
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single

- (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
 CATTCGGATG GGATCTTCAC GGATAG 26
- 5
- (2) INFORMATION FOR SEQ ID NO:16:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 24bp
- 10 (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
- 15 GAGCCCCGCC CGTGCTTACC GCAG 24
- (2) INFORMATION FOR SEQ ID NO:17:
- (i) SEQUENCE CHARACTERISTICS:
- 20 (A) LENGTH: 24bp
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
- 25 CACGCCGATG GGATCTTCAG CAAA 24
- (2) INFORMATION FOR SEQ ID NO:18:
- (i) SEQUENCE CHARACTERISTICS:
- 30 (A) LENGTH: 24bp
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
- 35 CCCGACCCGC TTGGCCATCA GGGA 24
- (2) INFORMATION FOR SEQ ID NO:19:
- 40 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 27 aa
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- 45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
- His Ile Asp Gly Ile Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gln
 1 5 10 15
 Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu
 20 25
- 50
- (2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 aa

(B) TYPE: amino acid

(C) STRANDEDNESS: single

5 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

10 His Ala Asp Gly Ile Phe Ser Lys Ala Tyr Arg Lys Leu Leu Gly Gln
1 5 10 15
Leu Ser Ala Arg Asn Tyr Leu His Ser Leu Met Ala Lys
20 25

Claims:

1. An isolated nucleic acid molecule including at least 25 contiguous nucleotides of the sequence shown in Seq. I.D. No. 1.
- 5 2. An isolated nucleic acid molecule according to claim 1 wherein the molecule includes at least 30 contiguous nucleotides of the sequence shown in Seq. I.D. No. 1.
3. An isolated nucleic acid molecule according to claim 1 wherein the molecule includes at least 50 contiguous nucleotides of the sequence shown in Seq. I.D. No. 1.
4. An isolated nucleic acid molecule according to claim 1 wherein the nucleic acid
10 molecule encodes a polypeptide capable of stimulating the release of pituitary growth hormone from chicken pituitary cells.
5. A nucleotide vector including a nucleic acid molecule according to claim 4.
6. A transgenic host cell produced by introducing into a host cell a nucleotide vector according to claim 5.
- 15 7. A method of producing a polypeptide capable of stimulating the release of pituitary growth hormone from chicken pituitary cells, the method comprising the steps of:
 - (a) providing a transgenic host cell according to claim 6;
 - (b) cultivating the cell under conditions supporting the production of the polypeptide; and
 - (c) harvesting the polypeptide.
- 20 8. A purified polypeptide produced according to the method of claim 7.
9. A composition for administration to poultry comprising a purified polypeptide according to claim 8.
10. An isolated nucleic acid molecule encoding a chicken neuropeptide precursor polypeptide, the polypeptide having an amino acid sequence selected from the group consisting of the
25 sequences shown in:
 - (a) Seq. I.D. No. 3;
 - (b) Seq. I.D. No. 7; or
 - (c) Seq. I.D. No. 9.
11. A nucleotide vector including a nucleic acid molecule according to claim 10.
- 30 12. A transgenic host cell produced by introducing into the host cell a nucleotide vector according to claim 11.
13. A method of producing a polypeptide capable of stimulating the release of pituitary growth hormone from chicken pituitary cells, the method comprising the steps of:
 - (a) providing a transgenic host cell according to claim 12;
 - 35 (b) cultivating the cell under conditions supporting the production of the polypeptide; and
 - (c) harvesting the polypeptide.
14. A purified polypeptide produced according to the method of claim 13.

15. A purified polypeptide having an amino acid sequence selected from group consisting of the sequences shown in:

- (a) Seq. I.D. No. 3;
- (b) Seq. I.D. No. 7; or
- (c) Seq. I.D. No. 9.

16. A purified chicken neuropeptide precursor polypeptide, wherein the polypeptide includes at least 20 consecutive amino acids selected from the amino acid sequences shown in:

- (a) Seq. I.D. No. 3;
- (b) Seq. I.D. No. 7; or
- (c) Seq. I.D. No. 9.

and wherein the polypeptide includes both a chicken GRF peptide and a chicken PACAP peptide.

17. An isolated nucleic acid molecule having a nucleotide sequence comprising at least 10 consecutive nucleotides of the sequence shown in Seq. I.D. No. 12, wherein the nucleic acid molecule encodes a polypeptide capable of stimulating the release of pituitary growth hormone from chicken pituitary cells.

18. An isolated nucleic acid molecule according to claim 17 wherein the nucleic acid molecule encodes a chicken GRF peptide having an amino acid sequence selected from the group consisting of the amino acid sequences shown in:

- (a) Seq. I.D. No. 4; or
- (b) Seq. I.D. No. 8.

19. A purified polypeptide encoded by a nucleic acid molecule according to claim 17.

20. A purified chicken GRF polypeptide having an amino acid sequence selected from the group consisting of the amino acid sequences shown in:

- (a) Seq. I.D. No. 4; and
- (b) Seq. I.D. No. 8.

21. An isolated DNA molecule wherein the molecule includes at least 10 consecutive nucleotides of the sequence shown in Seq. I.D. No. 13 and wherein the DNA molecule encodes a polypeptide capable of stimulating the release of pituitary growth hormone from chicken pituitary cells.

22. A DNA molecule according to claim 21 wherein the DNA molecule encodes a polypeptide having an amino acid sequence as shown in Seq. I.D. No. 13.

23. A DNA molecule according to claim 22 wherein the DNA molecule has a nucleotide sequence as shown in Seq. I.D. No. 5.

24. A recombinant DNA molecule including a nucleic acid molecule according to claim 4.

25. A transgenic non-human animal wherein the genome of the animal includes a recombinant DNA molecule according to claim 24.

26. A composition including a purified polypeptide encoded by a nucleic acid molecule according to claim 4, wherein the polypeptide is capable of stimulating the release of pituitary growth hormone from chicken pituitary cells.

5 27. An isolated nucleic acid molecule having a nucleotide sequence selected from the group consisting of the sequences shown in:

(a) Seq. I.D. No. 1 or its complementary strand;

(b) Seq. I.D. No. 4 or its complementary strand;

(c) Seq. I.D. No. 12 or its complementary strand; and

10 (d) sequences which hybridize under conditions of at least 75% stringency to the sequences defined in (a)-(c);

and wherein the nucleic acid molecule encodes a peptide capable of stimulating the release of pituitary growth hormone from chicken pituitary cells.

28. An isolated nucleic acid molecule according to claim 27 (d) wherein the nucleic acid molecule hybridizes under conditions of at least 90% stringency.

15




FIG. 1

2/4

FIG. 2 1/3

-----INTRON 2-----

4763 aggaatgactcctccttctgctactcttatttccactgtatggggttaagaagactcgtcacgctgggctgagcactggag 4842
 4843 cgagctcgctccgtcccgcaacggtcccgcggggacgggctgggacgtccggctgagcccgccgctgcttaccgca 4922
 4923 g CTG GAG GAG GTA TAC GAC GAC GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG 4980
 38 L E E E V Y D E D G N T L Q D F A L R 56

4981 GCA GGA GCC CCT GGG GGT GGC GGC GGC CCG CCG CCG TGG GGC AGG TGT ACG GCG CTG TAC 5040
 57 A G A P G G G G G P R P R W G R C T A L Y 76

5041 TAC CCG CCG GGA AAG AG gtgacagaggggcgcggataggccggggggggggggggaatgggaaacctaag 5114
 77 Y P P G K R 82

5115 ggccccggggagggccgggaaatatcgttaaltccgccccacactgggctgcgcgagcgggggggggggggggggag 5194
 5195 ggcgccctcggggatgggcgctgacgggcccgtgccccggcag G CAC GCC GAT GGG ATC TTC AGC AAA GCC 5263
 83 H A D G I F S K A 91

3/4

FIG. 2 2/3

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/CA 98/00033

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/16 C07K14/575 A61K38/22 A01K67/027 C07K14/60

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EMBL databank Accession number A61070 31-12-93 yasuhara t. XP002068607	1-9, 16, 21-24, 26
Y	see the whole document	17, 19, 25
X	WO 96 09064 A (UNIV TULANE ; ARIMURA AKIRA (US)) 28 March 1996 see figures 1,6; example 2	1-9, 16, 21, 24, 26
Y	WO 94 26897 A (UNIV VICTORIA INNOVAT DEV) 24 November 1994 see abstract; claims 41-45; figures 1-16	17, 19, 25
X	EP 0 404 034 A (TAKEDA CHEMICAL INDUSTRIES LTD) 27 December 1990 see claims 1-29	1-3
-/-		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (see specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the international search

18 June 1998

Date of mailing of the international search report

03/07/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gurdjian, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 98/00033

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>MCRORY, JOHN E. ET AL: "Expression and alternative processing of a chicken gene encoding both growth hormone-releasing hormone and pituitary adenylate cyclase-activating polypeptide"</p> <p>DNA CELL BIOL. (1997), 16(1), 95-102</p> <p>CODEN: DCEBE8;ISSN: 1044-5498, XP002068608</p> <p>see the whole document</p> <p>-----</p>	<p>1-24, 26-28</p>

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/CA 98/00033

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9609064 A	28-03-1996	WO 9609318 A	28-03-1996
		AU 3681095 A	09-04-1996
WO 9426897 A	24-11-1994	US 5695954 A	09-12-1997
		AU 6791594 A	12-12-1994
		EP 0699238 A	06-03-1996
		NO 954559 A	12-01-1996
EP 0404034 A	27-12-1990	JP 3022987 A	31-01-1991
		AT 127844 T	15-09-1995
		CA 2019363 A	20-12-1990
		DE 69022297 D	19-10-1995
		DE 69022297 T	22-02-1996
		US 5198542 A	30-03-1993
		US 5326860 A	05-07-1994